



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

The effects of walkability on physical activity and obesity: a prospective observational study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034882
Article Type:	Protocol
Date Submitted by the Author:	09-Oct-2019
Complete List of Authors:	Zhang, Yalan; The First Affiliated Hospital to Army Medical University, Health Management Centre Chen, Siyu; Southwest School of Medicine and First Affiliated Hospital, Army Medical University, Department of Epidemiology and Biostatistics Shi, Jiayang; The First Affiliated Hospital to Army Medical University, Health Management Centre Chen, Zongtao; Health Management Centre, The First Affiliated Hospital to Army Medical University
Keywords:	EPIDEMIOLOGY, SPORTS MEDICINE, CLINICAL PHYSIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

The effects of walkability on physical activity and obesity: a prospective observational study

Yannan Zhang^{1¶}, Siyu Chen^{2¶}, Jiayang Shi¹, Zongtao Chen^{1*}

¹Health Management Centre, First Affiliated Hospital, Army Medical University, Chongqing, P.R. China.

²Department of Epidemiology and Biostatistics, Southwest School of Medicine and First Affiliated Hospital, Army Medical University, Chongqing, P.R. China

*Corresponding author

E-mail: chenzongtao@126.com

¶These authors contributed equally to this work.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction

The prevalence of overweight and obesity is increasing worldwide, which could lead to a set of chronic and metabolic diseases. Physical activity is a modifiable factor for obesity, which was reported to be correlated with built environment. However, the effects of built environment on physical activity are controversial. Walkability is a convenient way to assess built environment. We aim to prospectively explore the relationship among walkability, physical activity, and obesity in Chinese participants in Chongqing, and provide evidence for future urban planning.

Methods and analysis

Participants will be recruited from people who receive health examinations in the Health Management Centre, the First Affiliated Hospital to Army Medical University. Exposures are workplace and residential addresses of the participants, which are transformed into Walkscore in the analysis. The primary outcomes are body mass index (BMI) calculated by the data collected at the date of health examination and daily steps during a 30-day follow-up period recorded by the WeChat mini application. Other health examination data of the participants will also be collected. Multivariate regression analysis will be performed to examine the relationship between exposures and outcomes.

Ethics and dissemination

The Protocol is approved by the Ethics Committee of the First Affiliated Hospital to Army Medical University (KY201839). The results will be actively disseminated through peer-review journals and conference publications.

Strengths and limitations of this study

This study is the first one to evaluate the effects of walkability on health in China as far as we know. It innovatively evaluates the effects of walkability on physical activity and obesity in a hilly city, which has potentials to unveil the unique feature of walkability in a hilly environment. The daily steps will be recorded by WeChat mini application on participants' smartphones, which will indicate the daily activity of participants. However, the application would fail to record data during swimming and other physical activities during which the participants do not carry their phones. The Walkscore could reflect the general situation of walkability in participants' address; however, it is unable to reveal the details in built environment.

Introduction

The prevalence of overweight and obesity has doubled worldwide since 1980, which is currently 5% in children and 12% in adults.¹ In 2015, the number of children and adults who suffered from obesity was 107.7 million and 603.7 million, respectively.² High body mass index (BMI), an indicator for obesity, was identified to be a risk factor for various chronic diseases, including cardiovascular disease, diabetes, chronic kidney disease, and cancers.² It is reported that Chinese overweight and obesity prevalence is 21.8% in 2007 and obesity rate in Chongqing is 10.3%.^{3, 4}

One of the modifiable risk factors of obesity and chronic diseases is physical inactivity.^{5, 6} Physical inactivity is partly due to insufficient activity during leisure time and an increase in sedentary behavior during occupational and domestic activities.⁷ Additionally, an increase in the use of "passive" modes of transport has also been associated with declining physical activity levels, which means less walking in daily life.⁷ Insufficient physical activity contributes to 6% of the disease burden of coronary heart disease, 7% of that of type 2 diabetes, 10% of that of breast cancer, and 10% of that of colon cancer.⁸ As reported, more than 533,000 deaths and more than 1.3 million deaths could be averted annually by reducing the prevalence of physical inactivity by 10% and 25%, respectively.⁸ Thus, in order to ameliorate physical inactivity, it is crucial to understand its associated factors and determinants. The factors associated with physical activity in high-income countries were reported to be age, sex, health status, self-efficacy, genetic factors, and motivation.⁹ At the level of population, the factors outside health sectors have been identified to be causally related to physical inactivity, for example, urban planning, transportation system, and built environment.⁹⁻¹¹

Walkability offers an alternative to assess the built environment, which is a key step in evaluating the effects of the built environment on physical activity.¹² However, there were disputes on these studies. A study published in *Nature* in 2017 with more than 700 thousand participants and 68 million days recorded revealed that higher walkability was associated with more daily steps, whose effect is stronger for females.¹² Porter and colleagues also indicated in a cohort study with 688 participants that as one aspect of the neighborhood environment, walkability is associated with physical activity among pregnant women.¹³ Other studies from Japan and North America also supported the positive effects of built environment on physical activity.¹⁴⁻¹⁶ However, a cohort study with 1819 households investigating moving to the former Olympic athletes' village in London discovered no effect associated with this living environment change on daily steps, indicating that ameliorating the built environment might be insufficient to enhance physical activity.¹⁷ A study with 161 older adult participants in Canada also showed that walkability was not associated with physical activity volume or intensity.¹⁸ In addition to these controversial evidences, there is no research of walkability effects on physical activity and health in China.

The factors of walkability usually include residential housing units, retail shops, public transportation, street-level movement density, the distance to behavior-related destinations.¹⁹ Some studies also take into account the population density, the street connectivity, land-use diversity, infrastructure and safety for walking, aesthetics, and crime influence.²⁰⁻²² Walkscore

(www.walkscore.com) is a user-friendly open composite walkability index. It could evaluate the walkability of a mail address or a city and is widely used in the studies investigating the relationship between walkability and health status.^{12, 23}

The evaluation of the walkability of a community and its effects on physical activity and health status of the residents in China could shed a light on urban design, laying a foundation for future urban planning policy and physical activity promotion interventions. In addition, there is a gap of research on the influences of walkability on the physical activity in a hilly city. This protocol is an observational, prospective cohort study of participants who receive physical examination in the First Affiliated Hospital to Army Medical University. The aim is to use Walkscore to evaluate the walkability of participants' residential and workplace addresses in Chongqing, a Chinese city, which is characterized by hilly topology and multi-commercial centres, and to analyze the relationships of walkability and physical activity with overweight, obesity, and physical signs such as blood glucose, lipids, and so on.

Materials and Methods

Study design and setting

Blood samples, clinical data, and addresses are collected prospectively from participants who receive physical examination in the Health Management Centre, First Affiliated Hospital to Army Medical University. Clinical and demographic data are recorded in the hospital's database. The daily walking steps and the home and workplace addresses of participants are collected by WeChat mini application. Blood samples are examined by the clinical laboratory of the hospital. Participants will be recruited from October 2019 to 2020 and followed up till 2023. The recruitment period will be extended if necessary. The recruitment process can be referred to Figure 1.

Participants

This is an open cohort study. Participants are eligible for inclusion if they satisfy the following criteria: an age between 16 and 65, using smart phones, habitual residents in the downtown area of Chongqing.

The exclusion criteria will be: 1. participants with the symptoms or signs of cardiovascular and cerebrovascular diseases, such as chest tightness, shortness of breath, and even chest pain, especially those whose symptoms get worse when climbing stairs or walking fast; 2. participants with diagnosed heart diseases, such as coronary heart diseases, hypertensive heart diseases, valvular heart diseases, and pulmonary heart diseases, who need to exercise based on principles of cardiac rehabilitation; 3. participants with other severe complications of diabetes, such as those with vision severely affected by eye diseases, those with balancing ability affected by peripheral neuropathy, those with diabetic foot, and those with renal dysfunction; 4. participants

whose movement is affected by musculoskeletal disorders, e.g. patients with musculoskeletal disorders and cardiopulmonary dysfunction; 5. participants who refuse to provide real and accurate information, or are not able to complete the questionnaire and physical examination; 6. participants who plan to migrate to other areas or leave for a long time (more than one year); 7. participants with secondary morbid obesity caused by congenital diseases, metabolic diseases, neurologic diseases and endocrine diseases. Participant inclusion and follow-up will be checked by the health managers and nurses in the Health Management Centre. Participants must be able to sign written informed consent after acknowledging the benefits and risks of this study.

The number of the sample size was calculated using the following formula:

$$n = \frac{\left(z_{\alpha} \sqrt{2pq} + z_{\beta} \sqrt{p_0 q_0 + p_1 q_1} \right)^2}{(p_1 - p_0)^2}$$

The parameters used in the calculation are: P_0 (the obesity prevalence in control group) as 10.3%,⁴ the supposed risk ratio (RR) between groups with high Walkscore and low Walkscore as 0.5, $\alpha = 0.05$, and $1 - \beta = 0.9$. In this formula, $p_1 = p_0 * RR = 5.15\%$, $\bar{p} = (p_0 + p_1)/2$, $\bar{q} = 1 - \bar{p}$, $q_0 = 1 - p_0$, and $q_1 = 1 - p_1$, $Z_{\alpha} = 1.96$, and $Z_{\beta} = 1.282$. Based on these parameters, the sample size in exposure group and control group should be 400, respectively. Concerning the possibility of loss of follow-up, we increased the sample size by 10% to 440 participants in each group. The final sample size is 880 in total.

Clinical data

During the process of inclusion, the following data were collected by the health managers and nurses:

1. Participant demographics: age, gender, height, marital status, and education.
2. Exposure: workplace address and residential address of the participants.
3. Lifestyle factors: smoking status, alcohol consumption, online food order habit, and so on.
4. Primary outcome: Body mass index (BMI), and everyday walking steps are recorded by a WeChat mini application. Every year, the monthly daily steps will be collected after physical examination in the hospital. BMI was calculated by the weight in kilograms divided by the square of the height in meters. Overweight and obesity were defined as a BMI of 24–27.9 kg/m² and a BMI ≥ 28 kg/m², respectively²⁴. The participants will authorize the researchers in this study to obtain the daily steps in 30 days collected by the WeChat mini application.
5. Secondary outcomes: metabolic profiles by blood tests; for example, cholesterol levels and blood glucose. Body composition was measured by a machine named InBody 220.
6. Identification of non-communicable diseases: e.g. hypertension, coronary artery disease, and diabetes.

1
2
3
4 **Biological samples**
5

6 The participants should be fasting for 12 to 14 hours before examination. The blood samples are
7 collected by nurses in health management Centre in the morning. A sum of 5mL blood was
8 collected in the yellow tube with inert separating gel for cholesterol and glucose testing. A total
9 of 2mL blood for blood routine test was stored in a purple tube with
10 ethylenediaminetetraacetic acid (EDTA) as anticoagulant.
11
12

13
14 **Assay methods**
15

16 The blood samples are analyzed by automated biochemical analyzer, with the series number of
17 Beckman AU5811. Total cholesterol was tested by the cholesteroxidase (CHO) enzyme method.
18 Triglyceride was tested by the glycerol phosphate dehydrogenase and peroxidase (GPO-POD)
19 method.
20
21

22
23 **Physical examination**
24

25 The physical examination included the measurement of height, body weight, blood pressure, and
26 body component following the guidelines of the Health Management Centre. The blood pressure
27 was evaluated by electronic sphygmomanometer (Omron, type : B-203RV III C). The body
28 composition was assessed by a machine named inbody 220.
29
30

31
32 **Statistical methods**
33

34 Descriptive statistics is performed to analyze the distribution of the data. Missing data was
35 addressed by deletion or last observation carried forward based on specific case status. Single
36 variable analysis will be implemented to analyze the correlations between exposures, lifestyle
37 factors (potential confounders), and outcomes. The participants will be divided into four groups
38 by the quartiles of the Walkscore with regard of workplace address and residential address,
39 respectively (In this way, we decide the exposure degree). The lifestyle factors and outcomes will
40 be compared among groups. Multivariate linear regression will be conducted taken BMI and
41 daily steps as dependent variables, respectively. Sensitivity analysis will be implemented by
42 leave-one-out method.
43
44
45
46
47

48 **Ethics and dissemination**
49

50 The Protocol is approved by the Ethics Committee of the First Affiliated Hospital to Army Medical
51 University (KY201839). All the participants will receive consultation about the benefits and
52 possible risks of the study from health managers and nurses, and endow written informed
53 consent before enrollment. All the participants will be informed that they can withdraw from the
54 study at any time for any reason. The withdrawal cases will be discarded and related information
55 will be deleted from the database of the study.
56
57

58
59 The sample volume of blood for the study is 11 per participant-visit and maximum 55 for five
60

years. The blood sampling process is part of procedure of physical examination and this study acquires the data use authority after the recruitment. The participants will be contacted and informed the results of the physical examination. The researchers of this study will be responsible for implementing the study adhering to the Declaration of Helsinki.

We plan to analyze and publish study results according to the STROBE guidelines. Results will be published in international and peer-reviewed scientific journals. Negative, positive or inconclusive results will be published.

Study Status

Participant recruitment will start in October 2019 and is expected to continue until 2020, with follow-up until 2023. The follow-up will be sustained by contacting with participants and requiring body examination by phone. Currently, the daily steps collector of the WeChat mini application is under development. The study was registered in Chinese Clinical Trial Registry (ChiCTR) and the registration number is ChiCTR1800017680.

Discussion and potential limitations

This observational and prospective study could innovatively provide evidence of the relationship among walkability, obesity, and physical activity in China. It will also provide evidence of the influence of built environment on physical activity in a hilly city, Chongqing. We hypothesized that the walkability, physical activity, and obesity status are strongly associated with each other.

There are some limitations in the collection of physical activity. The WeChat mini application can only record the daily steps when the participants walk with their phone. Like other studies, activities without carrying phones such as swimming and ball games will not be recorded in the data collection procedure.¹² Moreover, more than 30 days' collection needs second authorization which is less adherent; thus the researchers could only collect the data of 30 days for convenience. In order to compensate for this limitation, the participants will be recruited all year round and the researchers will ask for a second authorization of daily step collection in the follow-up visit.

Moreover, Walkscore is based on an online calculation website which has not opened the algorithm. Other walkability evaluation tools such as Neighborhood Environment Walkability Scale (NEWS) and Pedestrian Environment Quality Index (PEQI) depend on the evaluation of geographic information system (GIS), the score process of which is relatively clean; however, the practice is more complex.²⁵⁻²⁷ Thus, we decide to choose Walkscore for the primary analysis. If the results could indicate the relationship between walkability and obesity, we could further analyze the component factors of walkability in following analysis.

Funding: there is no funding.

Acknowledgements: Thanks to Dr. Zhizhong Gong and Dr. Baoqi Fan for their suggestions of this study.

Competing interests: All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/coi_disclosure.pdf and declare: no support from any organization for the submitted work; no financial relationships with any organization that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.

Contributors: SC and YZ are joint first authors. SC contributed to study concept. SC wrote the first draft of the protocol manuscript. ZC supervised the process. YZ and JS revised the manuscript after feedback from all authors. All authors reviewed the manuscript and approved the final version of the manuscript.

Data sharing statement: No additional data are available.

Patient consent: Consent will be obtained in the enrollment process.

Ethics approval: The Protocol is approved by the Ethics Committee of the first affiliated hospital to Army Medical University (KY201839).

References:

1. Gregg EW, Shaw JE. Global Health Effects of Overweight and Obesity. *N Engl J Med*. 2017;377(1):80-1.
2. Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. *N Engl J Med*. 2017;377(1):13-27.
3. Wang Y, Mi J, Shan XY, Wang QJ, Ge KY. Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China. *Int J Obes (Lond)*. 2007;31(1):177-88.
4. Shuping Z. Changes in prevalence of overweight and obesity in a community in Chongqing from 2003 - 2013. *Chongqing Medicine*. 2017;46(29):4108.
5. Stringhini S, Carmeli C, Jokela M, Avendano M, Muennig P, Guida F, et al. Socioeconomic status and the 25 x 25 risk factors as determinants of premature mortality: a multicohort study and meta-analysis of 1.7 million men and women. *LANCET*. 2017;389(10075):1229-37.
6. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *LANCET*. 2016;388(10053):1659-724.
7. World Health Organization. Physical Inactivity: A Global Public Health Problem.; 2019.
8. Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life

expectancy. *LANCET*. 2012;380(9838):219-29.

9. Bauman AE, Reis RS, Sallis JF, Wells JC, Loos RJ, Martin BW. Correlates of physical activity: why are some people physically active and others not? *LANCET*. 2012;380(9838):258-71.
10. Sallis JF, Cerin E, Conway TL, Adams MA, Frank LD, Pratt M, et al. Physical activity in relation to urban environments in 14 cities worldwide: a cross-sectional study. *LANCET*. 2016;387(10034):2207-17.
11. Karmeniemi M, Lankila T, Ikaheimo T, Koivumaa-Honkanen H, Korpelainen R. The Built Environment as a Determinant of Physical Activity: A Systematic Review of Longitudinal Studies and Natural Experiments. *ANN BEHAV MED*. 2018;52(3):239-51.
12. Althoff T, Sosic R, Hicks JL, King AC, Delp SL, Leskovec J. Large-scale physical activity data reveal worldwide activity inequality. *NATURE*. 2017;547(7663):336-9.
13. Porter AK, Rodriguez DA, Frizzelle BG, Evenson KR. The Association between Neighborhood Environments and Physical Activity from Pregnancy to Postpartum: a Prospective Cohort Study. *J URBAN HEALTH*. 2019.
14. Murillo R, Reesor LM, Hernandez DC, Obasi EM. Neighborhood Walkability and Aerobic Physical Activity among Latinos. *AM J HEALTH BEHAV*. 2019;43(4):802-11.
15. Larouche R, Blanchette S, Faulkner G, Riazi N, Trudeau F, Tremblay MS. Correlates of Children's Physical Activity: A Canadian Multisite Study. *Med Sci Sports Exerc*. 2019.
16. Amagasa S, Inoue S, Fukushima N, Kikuchi H, Nakaya T, Hanibuchi T, et al. Associations of neighborhood walkability with intensity- and bout-specific physical activity and sedentary behavior of older adults in Japan. *GERIATR GERONTOL INT*. 2019.
17. Nightingale CM, Limb ES, Ram B, Shankar A, Clary C, Lewis D, et al. The effect of moving to East Village, the former London 2012 Olympic and Paralympic Games Athletes' Village, on physical activity and adiposity (ENABLE London): a cohort study. *Lancet Public Health*. 2019;4(8):e421-30.
18. Chudyk AM, McKay HA, Winters M, Sims-Gould J, Ashe MC. Neighborhood walkability, physical activity, and walking for transportation: A cross-sectional study of older adults living on low income. *BMC GERIATR*. 2017;17(1):82.
19. Sarkar C, Webster C, Gallacher J. Neighbourhood walkability and incidence of hypertension: Findings from the study of 429,334 UK Biobank participants. *Int J Hyg Environ Health*. 2018;221(3):458-68.
20. Creatore MI, Glazier RH, Moineddin R, Fazli GS, Johns A, Gozdyra P, et al. Association of Neighborhood Walkability With Change in Overweight, Obesity, and Diabetes. *JAMA*. 2016;315(20):2211-20.
21. James P, Kioumourtoglou MA, Hart JE, Banay RF, Kloog I, Laden F. Interrelationships Between Walkability, Air Pollution, Greenness, and Body Mass Index. *EPIDEMIOLOGY*. 2017;28(6):780-8.
22. Yu R, Cheung O, Lau K, Woo J. Associations between Perceived Neighborhood Walkability and Walking Time, Wellbeing, and Loneliness in Community-Dwelling Older Chinese People in Hong Kong. *Int J Environ Res Public Health*. 2017;14(10).
23. Brath H, Kim SJ, Savage RD, Bronskill SE, Rochon PA, Stall NM. Neighborhood Walkability of Retirement Homes: A Cross-Sectional Cohort Study. *J AM MED DIR ASSOC*. 2019;20(1):105-6.
24. Hu L, Huang X, You C, Li J, Hong K, Li P, et al. Prevalence of overweight, obesity, abdominal obesity and obesity-related risk factors in southern China. *PLOS ONE*. 2017;12(9):e183934.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

25. Kim H, Choi Y, Ma J, Hyung K, Miyashita M, Lee S. The Neighborhood Environment Walkability Scale for the Republic of Korea: Reliability and Relationship with Walking. IRAN J PUBLIC HEALTH. 2016;45(11):1427-35.

26. Adlakha D, Hipp JA, Brownson RC. Adaptation and Evaluation of the Neighborhood Environment Walkability Scale in India (NEWS-India). Int J Environ Res Public Health. 2016;13(4):401.

27. Messer LC, Jagai JS, Rappazzo KM, Lobdell DT. Construction of an environmental quality index for public health research. Environ Health. 2014;13(1):39.




Figure 1. Flow chart

506x378mm (72 x 72 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract P2 (b) Provide in the abstract an informative and balanced summary of what was done and what was found P2
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported P3
Objectives	3	State specific objectives, including any prespecified hypotheses P3
Methods		
Study design	4	Present key elements of study design early in the paper P5-P6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection P4-P7
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up P4-P5 <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed P6 <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable P4-P7
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group P6-P7
Bias	9	Describe any efforts to address potential sources of bias P6-P7
Study size	10	Explain how the study size was arrived at P6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why P7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding P7 (b) Describe any methods used to examine subgroups and interactions P7 (c) Explain how missing data were addressed P7 (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed P7 <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses P6

Continued on next page

Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount) P7
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18	Summarise key results with reference to study objectives
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias P7
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence P7
Generalisability	21	Discuss the generalisability (external validity) of the study results P7
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

中国人民解放军陆军军医大学第一附属医院伦理委员会
临床试验审批件

批件号: KY201839

项目名称	城市可步行性对超重和肥胖影响的前瞻性队列研究
试验分类	<input type="checkbox"/> 注册药物 <input type="checkbox"/> 注册器械 <input checked="" type="checkbox"/> 临床科研 <input type="checkbox"/> 其他
临床分期	药物适用: <input type="checkbox"/> I 期 <input type="checkbox"/> II 期 <input type="checkbox"/> III 期 <input type="checkbox"/> IV 期 <input type="checkbox"/> 其他: 器械适用: <input type="checkbox"/> 临床试用 <input type="checkbox"/> 临床验证 <input type="checkbox"/> 其他:
申办单位	无
申请科室	健康管理科
主要研究者/职称	陈宗涛/副研究员
审查意见	审评说明: 本伦理委员会于 2018 年 7 月 10 日对该项目研究方案、知情同意书等有关材料进行了会议审查, 结果为“作必要修正后同意”(详见“修改通知”)。研究者修改后再次递交, 伦理委员会经快速审查认为总体上: 研究项目成员资格具备, 送审资料完备, 临床研究方案、知情同意书等材料符合伦理要求, 同意进行以上项目的临床研究。
	评审结论: 同意
	持续审查频率: <input type="checkbox"/> 3 个月 <input type="checkbox"/> 6 个月 <input checked="" type="checkbox"/> 12 个月 <input type="checkbox"/> 其他:
批准材料	1. 初审申请表 2. 复审申请表 3. 研究方案 (版本号: C1.1 日期: 2018.07.20) 4. 知情同意书 (版本号: C1.1 日期: 2018.07.20) 5. 伦理学申明 6. 主要研究者简历 7. 病例报告表 (日期: 2018.06.06) 8. 主要参考文献
批件有效期	根据本研究预期研究周期 5 年, 批件的有效期从批准之日起至 2023 年月 7 月 30 日

BMJ Open

The effects of walkability on physical activity and obesity: a prospective observational study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034882.R1
Article Type:	Protocol
Date Submitted by the Author:	13-Mar-2020
Complete List of Authors:	Zhang, Yalan; The First Affiliated Hospital to Army Medical University, Health Management Centre Chen, Siyu; Southwest School of Medicine and First Affiliated Hospital, Army Medical University, Department of Epidemiology and Biostatistics Shi, Jiayang; The First Affiliated Hospital to Army Medical University, Health Management Centre Chen, Zongtao; Health Management Centre, The First Affiliated Hospital to Army Medical University
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Epidemiology, Public health, Sports and exercise medicine
Keywords:	EPIDEMIOLOGY, SPORTS MEDICINE, CLINICAL PHYSIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

The effects of walkability on physical activity and obesity: a prospective observational study protocol

Yalan Zhang^{1¶}, Siyu Chen^{2¶}, Jiayang Shi¹, Zongtao Chen^{1*}

¹Health Management Centre, First Affiliated Hospital, Army Medical University, Chongqing, P.R. China.

²Department of Epidemiology and Biostatistics, Southwest School of Medicine and First Affiliated Hospital, Army Medical University, Chongqing, P.R. China

*Corresponding author

E-mail: chenzongtao@126.com

¶These authors contributed equally to this work.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction

The prevalence of overweight and obesity is increasing worldwide, which could lead to a set of chronic and metabolic diseases. Physical activity is a modifiable factor for obesity, which was reported to be correlated with built environment. However, the effects of built environment on physical activity are not consistent. Walkability is a convenient way to assess built environment. We aim to prospectively explore the relationship among walkability, physical activity, and obesity in Chinese participants in Chongqing, and provide evidence for future urban planning.

Methods and analysis

Participants will be recruited from people who receive health examination in the Health Management Centre, the First Affiliated Hospital to Army Medical University. Exposures are workplace and residential addresses of the participants, which are transformed into WalkScore in the analysis. The primary outcomes are body mass index (BMI) calculated by the data collected at the date of health examination and daily walking steps during a 30-day follow-up period recorded by the WeChat mini application. Other health examination data of the participants will also be collected. Multivariate regression analysis will be performed to examine the relationship between exposures and outcomes.

Ethics and dissemination

The Protocol is approved by the Ethics Committee of the First Affiliated Hospital to Army Medical University (KY201839). The results will be actively disseminated through peer-review journals and conference publications.

Strengths and limitations of this study

This study is the first one to evaluate the effects of walkability on health in China as far as we know. It innovatively evaluates the effects of walkability on physical activity and obesity in a hilly city, which has potentials to unveil the unique feature of walkability in a hilly environment. The daily walking steps will be recorded by WeChat mini application on participants' smartphones, which will indicate the daily activity of participants. However, the application would fail to record data during swimming and other physical activities during which the participants do not carry their phones. The WalkScore could reflect the general situation of walkability in participants' address; however, it is unable to reveal the details in built environment.

Introduction

The prevalence of overweight and obesity has doubled worldwide since 1980, which is currently 5% in children and 12% in adults.¹ In 2015, the number of children and adults who suffered from obesity was 107.7 million and 603.7 million, respectively.² High body mass index (BMI), an indicator for obesity, was identified to be a risk factor for various chronic diseases, including cardiovascular disease, diabetes, chronic kidney disease, and cancers.² China Health and Nutrition Survey showed the rate of obesity and overweight in adults increased from 25.1% to 39.6% from 1997 to 2009.³ The updated prevalence of overweight and obesity were reported to be 25.8% and 7.9%, respectively, in 2017.⁴ It is reported that the obesity rate in Chongqing in Southwestern China is 10.3%.^{5, 6}

One of the modifiable risk factors of obesity and chronic diseases is physical inactivity.^{7, 8} Physical inactivity is partly due to insufficient activity during leisure time and an increase in sedentary behavior during occupational and domestic activities.⁹ Additionally, an increase in the use of "passive" modes of transport has also been associated with declining physical activity levels, which means less walking or any human powered movement in daily life.⁹ Insufficient physical activity contributes to 6% of the disease burden of coronary heart disease, 7% of that of type 2 diabetes, 10% of that of breast cancer, and 10% of that of colon cancer.¹⁰ As reported, more than 533,000 deaths and more than 1.3 million deaths could be averted annually by reducing the prevalence of physical inactivity by 10% and 25%, respectively.¹⁰ Thus, in order to ameliorate physical inactivity, it is crucial to understand its associated factors and determinants. The factors associated with physical activity in high-income countries were reported to be age, sex, health status, self-efficacy, genetic factors, and motivation.¹¹ At the level of population, the factors outside health sectors have been identified to be causally related to physical inactivity, for example, urban planning, transportation system, and built environment.¹¹⁻¹³

Walkability is a key step in evaluating the effects of the built environment on physical activity.¹⁴ However, there have been inconsistency with respect to built environment, walkability, physical activity, and health. A study published in *Nature* in 2017 with more than 700 thousand participants and 68 million days recorded revealed that higher walkability was associated with more daily walking steps, whose effect was stronger for females.¹⁴ Porter and colleagues also indicated in a cohort study with 688 participants that as one aspect of the neighborhood environment, walkability was associated with physical activity among pregnant women.¹⁵ Other studies from Japan and North America also supported the positive effects of built environment on physical activity.¹⁶⁻¹⁸ In a middle size city Bengbu in Eastern China, researchers observed about at least 30% lower risk of cardiovascular diseases were associated with moderate to high levels of WalkScore, compared with controls with low WalkScore.¹⁹ However, a cohort study with 1819 households investigating moving to the former Olympic athletes' village in London discovered no effect associated with this living environment change on daily walking steps, indicating that ameliorating the built environment might be insufficient to enhance physical activity.²⁰ A study with 161 older adult participants in Canada also showed that walkability was not associated with physical activity volume or intensity.²¹ A study in a small city in China called Yuncheng also showed no positive associations of land-use mix and walking

duration.²² In addition to these consistent evidence, there is no research of walkability effects on physical activity and health in China.

The factors of walkability usually include residential housing units, retail shops, public transportation, street-level movement density, the distance to behavior-related destinations.²³ Residential housing units are a house, apartment, group of rooms, or a single room for occupancy as a separate living unit, which could predict the population allocation in an area.²⁴ Retail shops are one kind of points of interest, which serve for non-residential uses and can enhance the motivation of walking.²⁵ Well-connected streets, which are represented by the street-level movement density and the distance to behavior-related destinations, as well as the proximate access to public transportation are crucial characteristics of a walkable neighborhood.²⁶ Some studies also take into account the population density, the street connectivity, land-use diversity, infrastructure and safety for walking, aesthetics, and crime influence.²⁷⁻²⁹ WalkScore (www.WalkScore.com) is a user-friendly open composite walkability index. It could evaluate the walkability of a mail address or a city and is widely used in the studies investigating the relationship between walkability and health status.^{14, 30}

The evaluation of the walkability of a community and its effects on physical activity and health status of the residents in China could shed a light on urban design, laying a foundation for future urban planning policy and physical activity promotion interventions. Additionally, there is a gap of research on the influences of walkability on the physical activity in a hilly city. This protocol is an observational, prospective cohort study of participants who receive physical examination in the First Affiliated Hospital to Army Medical University. The location of our protocol is Chongqing, a Chinese city, with multi-commercial centres, which is characterized by a unique hilly topology with two rivers, Yangtze and Jialing. The aim is to analyze the relationships among walkability, physical activity, and obesity in the residents in Chongqing for future urban planning reference. A map and a photo with the hilly topography of Chongqing are showed in Supplementary Figure 1.

Materials and Methods

Study design and setting

Blood samples, clinical data, addresses, and related variables are collected prospectively from participants who receive physical examination in the Health Management Centre, First Affiliated Hospital to Army Medical University. Clinical and demographic data are recorded in the hospital's database. The daily walking steps of participants are collected by WeChat mini application. Blood samples are examined by the clinical laboratory of the hospital. The addresses and the part of listed variables in Table 1 will be collected by questionnaire. Participants will be recruited from October 2019 to 2020 and followed up till 2023. The recruitment period will be extended if necessary. Moreover, we will include the participants who had pre-existing appointment if he/she meets the inclusion/exclusion criteria. We need to require this kind of participants to provide home and workplace addresses on the first visit and fill questionnaire on the second visit after recruitment. The recruitment process can be referred to Figure 1.

150 Table 1. All measured variables.

Variable category	Name of variable	Normal limits or categories	Definition of variables	Sources of data
Primary Outcomes	Body mass index	18.5-24kg/m ²	Outcome	Calculate from health examination data
	Daily walking steps in one month		Outcome and mediator	Wechat mini application
Secondary Outcomes	Fasting blood glucose (GLU)	3.6-6.1 (mmol/L)	Outcome	Health examination
	Total cholesterol (TC)	3.1-5.7 (mmol/L)	Outcome	Health examination
	Triglyceride (Tg)	0.4-1.73 (mmol/L)	Outcome	Health examination
	Low density lipoprotein cholesterol (LDL-C)	2.07-3.1 (mmol/L)	Outcome	Health examination
	High density lipoprotein cholesterol (HDL-C)	0.9-2 (mmol/L)	Outcome	Health examination
	Body composition	Mass percentage of fat	Outcome	Health examination
Other variables	Height			Health examination
	Weight			Health examination
	Age	16 - 65 years old	Possible confounding	Questionnaire
	Gender	Male; female	Possible confounding	Questionnaire
	Job		Possible confounding	Questionnaire
	Education	Under primary school; primary school, middle school; bachelor; master and above	Possible confounding	Questionnaire
	WalkScore corresponding	0-100	Exposure	Calculate from questionnaire

bmjopen-2019-034882 on 19 October 2020. Downloaded from <http://bmjopen.bmj.com/> on April 9, 2024 by guest. Protected by copyright.

	to home address								Information	
	WalkScore	corresponding	0-100		Exposure				Calculate from questionnaire	
	to workplace address									Information
	Smoking status		Giving up; sometimes frequently smoke	never; smoke;	Other factors will influence outcome				Questionnaire	
	Alcohol consumption		Giving up; sometimes frequently drink	never; drink;	Other factors will influence outcome				Questionnaire	
	Online food order habit		Never; sometimes frequently order	order;	Possible confounding				Questionnaire	
	Eating diet		More details showed in questionnaire	showed in	Other factors will influence outcome				Questionnaire	
	Physical activity		More details showed in questionnaire	showed in	Possible confounding				Questionnaire	

Participants

This is an open cohort study. Participants are eligible for inclusion if they satisfy the following criteria: an age between 16 and 65, using smart phones, habitual residents in the downtown area of Chongqing.

The exclusion criteria will be: 1. participants with the symptoms or signs of cardiovascular and cerebrovascular diseases, such as chest tightness, shortness of breath, and even chest pain, especially those whose symptoms get worse when climbing stairs or walking fast; 2. participants with diagnosed heart diseases, such as coronary heart diseases, hypertensive heart diseases, valvular heart diseases, and pulmonary heart diseases, who need to exercise based on principles of cardiac rehabilitation; 3. participants with other severe complications of diabetes, such as those with vision severely affected by eye diseases, those with balancing ability affected by peripheral neuropathy, those with diabetic foot, and those with renal dysfunction; 4. participants whose movement is affected by musculoskeletal disorders, e.g. patients with musculoskeletal disorders and cardiopulmonary dysfunction; 5. participants who refuse to provide real and accurate information, or are not able to complete the questionnaire and health examination; 6. participants who plan to migrate to other areas or leave for a long time (more than one year); 7. participants with secondary morbid obesity caused by congenital diseases, metabolic diseases, neurologic diseases and endocrine diseases. Participant inclusion and follow-up will be checked by the health managers and nurses in the Health Management Centre. Participants must be able to sign written informed consent after acknowledging the benefits and risks of this study.

The number of the sample size was calculated using the following formula:

$$n = \frac{\left(z_{\alpha} \sqrt{2\bar{p}\bar{q}} + z_{\beta} \sqrt{p_0 q_0 + p_1 q_1} \right)^2}{(p_1 - p_0)^2}$$

The parameters used in the calculation are: P_0 (the obesity prevalence in control group) as 10.3%,⁶ the supposed risk ratio (RR) between groups with high WalkScore and low WalkScore as 0.5, $\alpha = 0.05$, and $1 - \beta = 0.9$. In this formula, $p_1 = p_0 * RR = 5.15\%$, $\bar{p} = (p_0 + p_1)/2$, $\bar{q} = 1 - \bar{p}$, $q_0 = 1 - p_0$, and $q_1 = 1 - p_1$, $Z_{\alpha} = 1.96$, and $Z_{\beta} = 1.282$. Based on these parameters, the sample size in exposure group and control group should be 400, respectively. Concerning the possibility of loss of follow-up, we increased the sample size by 10% to 440 participants in each group. The final sample size is 880 in total.

Clinical data

During the process of inclusion, the following data were collected by the questionnaire and health examination procedure as well as Wechat mini application:

1. Participant demographics: age, gender, height, marital status, and education.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

2. Exposure: workplace address and residential address of the participants.
3. Lifestyle factors: smoking status, alcohol consumption, online food order habit, eating diet, and physical activity
4. Primary outcomes: Body mass index (BMI), and everyday walking steps are recorded by a WeChat mini application. Every year, the monthly daily walking steps will be collected after physical examination in the hospital. BMI was calculated by the weight in kilograms divided by the square of the height in meters. Overweight and obesity were defined as a BMI of 24–27.9 kg/m² and a BMI ≥ 28 kg/m², respectively.⁴ The participants will authorize the researchers in this study to obtain the daily walking steps in 30 days collected by the WeChat mini application.
5. Secondary outcomes: metabolic profiles by blood tests; for example, cholesterol levels and blood glucose. Body composition was measured by a machine named inbody 220.
6. Identification of non-communicable diseases: e.g. hypertension, coronary artery disease, and diabetes.

The questionnaire filled by participants under nurses' guidance includes the questions of participant demographics, exposure, lifestyle factors. We attached the full version of the questionnaire in Supplementary File 1. The measured variables, primary outcome, and secondary outcomes as well as possible confoundings are listed in Table 1. The variables in detail are showed in Supplementary File 2. The relationships among different variables are illustrated in a causal diagram in Supplementary Figure 2.

Biological samples

The participants should be fasting for 12 to 14 hours before health examination. The blood samples are collected by nurses in the Health Management Centre in the morning. A sum of 5mL blood was collected in the yellow tube with inert separating gel for cholesterol and glucose testing. A total of 2mL blood for blood routine test was stored in a purple tube with ethylenediaminetetraacetic acid (EDTA) as anticoagulant.

Assay methods

The blood samples are analyzed by automated biochemical analyzer, with the series number of Beckman AU5811. Total cholesterol was tested by the cholesteroloxidase (CHO) enzyme method. Triglyceride was tested by the glycerol phosphate dehydrogenase and peroxidase (GPO-POD) method.

Physical examination

The physical examination included the measurement of height, body weight, blood pressure, and body component following the guidelines of the Health Management Centre. The blood pressure was evaluated by electronic sphygmomanometer (Omron, type : B-203RV III C). The body composition was assessed by a machine named inbody 220.

WalkScore

WalkScore measures pedestrian friendliness by analyzing the distance to point of interest, population density, block length, and intersection density. Data sources are from Google, Factual, Great Schools, Open Street Map, the U.S. Census, Localeze, and places added by the Walk Score user community.³¹ The algorithm of WalkScore is not disclosed in its official website. The formula³² of WalkScore illustrated in Tsinghua University is

$$\sum_{i=1, j=1}^{m,n} (W_i * S_{i,j} * D_{i,j}) * \frac{100}{15}$$

W_i is the weight of one kind of amenity. Table 2 shows the weights of different amenities.

Amenity category	Weight	Amenity category	Weight	Amenity category	Weight
convenience store	3	café/teahouse	2	school	1
restaurant	3	bank	1	bookstore	1
shop	2	park	1	entertainment places	1

Table 2. Weights of different amenities.

The letter of i stands for different kinds of amenities. The letter of j stands for different walking distance. $S_{i,j}$ stands for service scope of a specific amenity. $D_{i,j}$ stands for the attenuation coefficient based on distance from the calculated point to an amenity. Table 3 shows the attenuation coefficients based on the distances from the calculated point to an amenity.

Distances	Attenuation coefficients
<400 metres	1
400-800 metres	0.9
800-1200 metres	0.55
1200-1600 metres	0.25
1600-2400 metres	0.08
>2400 metres	Out of scope, which will not be calculated.

Table 3. Attenuation coefficients based on the distances.

The calculation of WalkScore is free, to obtain which we could type the name of calculated point into the official website and wait for the score. The limit of the score is 0-100. The WalkScore of residential address and workplace address will be calculated separately.

The following Table 4 describes the meanings of different WalkScore.

WalkScore	Description
90 - 100	Walker's Paradise: Daily errands do not require a car.
70 - 89	Very Walkable: Most errands can be accomplished on foot.
50 - 69	Somewhat Walkable: Some errands can be accomplished on foot.

25 - 49	Car-dependent: Most errands require a car.
0 - 24	Almost all errands require a car.

Table 4. Interpretations of different WalkScore.

Wechat mini application

Wechat is a cellphone application for communication used by more than a billion people.³³ The customers of it can send voice, video, photos, and text. On the basis of Wechat and its great number of users, the company of Wechat opens the resources to the public of developing different kinds of Wechat mini applications. Users could link its Wechat ID to Wechat mini application without download installment package and achieve data sharing through Wechat mini application. Through Wechat mini application, we could extract the daily walking steps of Wechat users in one month after customer agreement.

Statistical methods

The data analysis will be conducted after data collection in 2020. The prospective analysis will be implemented in 2023. Descriptive statistics is performed to analyze the distribution of the data. Missing data were addressed by deletion or last observation carried forward based on specific case status. Single variable analysis will be implemented to analyze the correlations between exposures, possible confoundings (i.e., online food order habit, education, job, physical activity), and outcomes. The participants will be divided into five groups by the categories of the WalkScore with regard to workplace address and residential address, respectively (In this way, we decide the exposure degree). The lifestyle factors and outcomes will be compared among groups. All the variables in causal diagrams will be compared between baseline and follow-ups. T-test will be used for the continuous variables, and Chi-square test or Analysis of Variance (ANNOVA) will be used for categorized variables. Multivariate linear regression will be conducted taken BMI and daily walking steps as dependent variables, respectively, as cross-sectional analyses, after data collection in 2020. Further longitudinal analyses with G estimation and inverse probability weight analysis will be conducted after data collection in 2023. Sensitivity analysis will be implemented by bootstrap method. With replacement from the original dataset, the bootstrap method enables estimation of the accuracy of an estimator by random sampling. The first step is to determine the ranges and variations of the independent variables, which are input into our multivariate linear regression. The second step is to generate independent variables based on the Sobol sequence by R package “randtoolbox”. The final step is to collect and process the simulation results, which can be used in sensitivity analysis through conducting multivariate linear regression.³⁴

Patient and public involvement

Our study is an observational study without intervention on participants. The development of the research question and outcome measures were informed by participants’ priorities,

experience, and preferences on the basis of informed consents. There is no participants' involvement in the study design. We recruit participants when conducting the study, but participants would not be the conductor of the study. The results are planned to disseminate to study participants.

Ethics and dissemination

The Protocol is approved by the Ethics Committee of the First Affiliated Hospital to Army Medical University (KY201839). All the participants will receive consultation about the benefits and possible risks of the study from health managers and nurses, and endow written informed consent before enrollment. All the participants will be informed that they can withdraw from the study at any time for any reason. The withdrawal cases will be discarded and related information will be deleted from the database of the study.

The sample volume of blood for the study is 11 per participant-visit and maximum 55 for five years. The blood sampling process is part of the procedure of physical examination and this study acquires the data use authority after the recruitment. The participants will be contacted and informed the results of the physical examination. The researchers of this study will be responsible for implementing the study adhering to the Declaration of Helsinki.

We plan to analyze and publish study results according to the STROBE guidelines. Results will be published in international and peer-reviewed scientific journals. Negative, positive or inconclusive results will be published.

Study Status

We collected demographic data, home addresses, and workplace addresses of participants in October 2019. We plan to check previous data and collect the data of health examination and questionnaire of participants in March to May 2020 and daily walking steps of participants by Wechat mini application in 2020 (in one month after health examination). We will continue follow-up in 2021-2023. The follow-up will be sustained by contacting with participants and requiring body examination by phone. Currently, the daily walking steps collector of the WeChat mini application has been developed. The study was registered in Chinese Clinical Trial Registry (ChiCTR) and the registration number is ChiCTR1800017680. The date of the study in a timeline is showed in Supplementary Table 1. There will be six waves of data collection.

Discussion and potential limitations

This observational and prospective study could innovatively provide evidence of the relationship among walkability, obesity, and physical activity in China. It will also provide evidence of the influence of built environment on physical activity in a hilly city, Chongqing. We hypothesized that the walkability, physical activity, and obesity status are strongly associated with each other. Our research hypothesis is that high WalkScore will be associated with the decrease of BMI. The

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

341 daily walking steps and metabolic profiles will be the mediators through the effect pathway from
342 WalkScore to BMI. We illustrate our hypothesis of causal diagram in Supplementary Figure 2.

343
344 There are some limitations in the collection of physical activity. The WeChat mini application can
345 only record the daily walking steps when the participants walk with their phone. Like other
346 studies, activities without carrying phones such as swimming and ball games will not be recorded
347 in the data collection procedure.¹⁴ Moreover, more than 30 days' collection needs second
348 authorization which is less adherent; thus the researchers could only collect the data of 30 days
349 for convenience. In order to compensate for this limitation, the participants will be recruited all
350 year round and the researchers will ask for a second authorization of daily step collection in the
351 follow-up visit.

352
353 Moreover, WalkScore is based on an online calculation website which has not opened the
354 algorithm officially. Other walkability evaluation tools such as Neighborhood Environment
355 Walkability Scale (NEWS) and Pedestrian Environment Quality Index (PEQI) depend on the
356 evaluation of geographic information system (GIS), the score process of which is relatively clean;
357 however, the practice is more complex.³⁵⁻³⁷ Thus, we decide to choose WalkScore for the primary
358 analysis. If the results could indicate the relationship between walkability and obesity, we could
359 further analyze the component factors of walkability in following analysis.

360
361
362
363
364
365 Legends

366
367 Figure 1. Flow chart of study.

368
369 Supplementary Figure 1A. Chongqing map.

370 It is the nine main districts of Chongqing extracted from Google map. The black point shows the
371 location of the First Affiliated Hospital to Army Medical University in Shapingba District.
372 Shapingba District is an old town with a lot of renowned high schools and universities.

373
374 Supplementary Figure 2B. Chongqing streetscape 1.

375 It is the streetscape in Egongyan Bridge, which shows the multi-dimensioned streets and
376 transportation ways of the city. Photographed by Yirui Gong.

377
378 Supplementary Figure 2. Causal diagram of measured variables.

379 Obesity and overweight is the primary outcome. WalkScore is the exposure variable. Daily
380 walking steps and metabolic profiles are the mediator from WalkScore to obesity. Job and
381 education are possible confoundings between WalkScore and daily walking steps. Physical
382 activity and mental health scores are possible confoundings between daily walking steps and
383 metabolic profiles. Online food order habit is possible confounding between WalkScore and
384 metabolic profiles. Eating habit, smoking, and alcohol consumption are other factors, which will

influence metabolic profiles.

Supplementary Table 1. Timeline of study conduction.

Funding: there is no funding.

Acknowledgements: Thanks to Dr. Zhizhong Gong and Dr. Baoqi Fan for their suggestions of this study. Thanks to patient/participant advisors in the Health Management Centre for their assistance. Thanks to SC's friends Ms. Sarah Higbee-Tindell, Ms. Chu Yu, and Ms. Qingya Wu for writing assistance of grammar modification.

Competing interests: All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/coi_disclosure.pdf and declare: no support from any organization for the submitted work; no financial relationships with any organization that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.

Contributors: SC and YZ are joint first authors. SC contributed to study concept and design. SC wrote the first draft of the protocol manuscript. ZC supervised the process. YZ and JS revised the manuscript after feedback from all authors. YZ coordinates the conducting of this study. All authors reviewed the manuscript and approved the final version of the manuscript.

Data sharing statement: No additional data are available.

Patient consent: Consent will be obtained in the enrollment process.

Ethics approval: The Protocol is approved by the Ethics Committee of the first affiliated hospital to Army Medical University (KY201839).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References:

1. Gregg EW, Shaw JE. Global Health Effects of Overweight and Obesity. *N Engl J Med*. 2017 2017-07-06;377(1):80-1.

2. Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. *N Engl J Med*. 2017 2017-07-06;377(1):13-27.

3. Wang YF, Sun MX, Xue H, Zhao WH, Yang XG, Zhu XY, et al. [Understanding the China Blue Paper on Obesity Prevention and Control and policy implications and recommendations for obesity prevention and control in China]. *Zhonghua Yu Fang Yi Xue Za Zhi*. 2019 2019-09-06;53(9):875-84.

4. Hu L, Huang X, You C, Li J, Hong K, Li P, et al. Prevalence of overweight, obesity, abdominal obesity and obesity-related risk factors in southern China. *PLOS ONE*. 2017 2017-01-20;12(9):e183934.

5. Wang Y, Mi J, Shan XY, Wang QJ, Ge KY. Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China. *Int J Obes (Lond)*. 2007 2007-01-01;31(1):177-88.

6. Shuping Z. Changes in prevalence of overweight and obesity in a community in Chongqing from 2003 - 2013. *Chongqing Medicine*. 2017;29(46):4108.

7. Stringhini S, Carmeli C, Jokela M, Avendano M, Muennig P, Guida F, et al. Socioeconomic status and the 25 x 25 risk factors as determinants of premature mortality: a multicohort study and meta-analysis of 1.7 million men and women. *LANCET*. 2017 2017-03-25;389(10075):1229-37.

8. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *LANCET*. 2016 2016-10-08;388(10053):1659-724.

9. Organization WH. Physical Inactivity: A Global Public Health Problem.; 2019.

10. Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. *LANCET*. 2012 2012-07-21;380(9838):219-29.

11. Bauman AE, Reis RS, Sallis JF, Wells JC, Loos RJ, Martin BW. Correlates of physical activity: why are some people physically active and others not? *LANCET*. 2012 2012-07-21;380(9838):258-71.

12. Sallis JF, Cerin E, Conway TL, Adams MA, Frank LD, Pratt M, et al. Physical activity in relation to urban environments in 14 cities worldwide: a cross-sectional study. *LANCET*. 2016 2016-05-28;387(10034):2207-17.

13. Karmeniemi M, Lankila T, Ikaheimo T, Koivumaa-Honkanen H, Korpelainen R. The Built Environment as a Determinant of Physical Activity: A Systematic Review of Longitudinal Studies and Natural Experiments. *ANN BEHAV MED*. 2018 2018-02-17;52(3):239-51.

14. Althoff T, Sosic R, Hicks JL, King AC, Delp SL, Leskovec J. Large-scale physical activity data reveal worldwide activity inequality. *NATURE*. 2017 2017-07-20;547(7663):336-9.

15. Porter AK, Rodriguez DA, Frizzelle BG, Evenson KR. The Association between Neighborhood Environments and Physical Activity from Pregnancy to Postpartum: a Prospective Cohort Study. *J URBAN HEALTH*. 2019 2019-10-01;96(5):703-19.
16. Murillo R, Reesor LM, Hernandez DC, Obasi EM. Neighborhood Walkability and Aerobic Physical Activity among Latinos. *AM J HEALTH BEHAV*. 2019 2019-07-01;43(4):802-11.
17. Larouche R, Blanchette S, Faulkner G, Riazi N, Trudeau F, Tremblay MS. Correlates of Children's Physical Activity: A Canadian Multisite Study. *Med Sci Sports Exerc*. 2019 2019-12-01;51(12):2482-90.
18. Amagasa S, Inoue S, Fukushima N, Kikuchi H, Nakaya T, Hanibuchi T, et al. Associations of neighborhood walkability with intensity- and bout-specific physical activity and sedentary behavior of older adults in Japan. *GERIATR GERONTOL INT*. 2019 2019-09-01;19(9):861-7.
19. Jia X, Yu Y, Xia W, Masri S, Sami M, Hu Z, et al. Cardiovascular diseases in middle aged and older adults in China: the joint effects and mediation of different types of physical exercise and neighborhood greenness and walkability. *ENVIRON RES*. 2018 2018-11-01;167:175-83.
20. Nightingale CM, Limb ES, Ram B, Shankar A, Clary C, Lewis D, et al. The effect of moving to East Village, the former London 2012 Olympic and Paralympic Games Athletes' Village, on physical activity and adiposity (ENABLE London): a cohort study. *Lancet Public Health*. 2019 2019-08-01;4(8):e421-30.
21. Chudyk AM, McKay HA, Winters M, Sims-Gould J, Ashe MC. Neighborhood walkability, physical activity, and walking for transportation: A cross-sectional study of older adults living on low income. *BMC GERIATR*. 2017 2017-04-10;17(1):82.
22. Sun Z, Lai KY, Bell S, Scott I, Zhang X. Exploring the Associations of Walking Behavior with Neighborhood Environments by Different Life Stages: A Cross-Sectional Study in a Smaller Chinese City. *Int J Environ Res Public Health*. 2019 2019-12-28;17(1).
23. Sarkar C, Webster C, Gallacher J. Neighbourhood walkability and incidence of hypertension: Findings from the study of 429,334 UK Biobank participants. *Int J Hyg Environ Health*. 2018 2018-04-01;221(3):458-68.
24. Michanowicz DR, Williams SR, Buonocore JJ, Rowland ST, Konschnik KE, Goho SA, et al. Population allocation at the housing unit level: estimates around underground natural gas storage wells in PA, OH, NY, WV, MI, and CA. *Environ Health*. 2019 2019-07-08;18(1):58.
25. Zandieh R, Flacke J, Martinez J, Jones P, van Maarseveen M. Do Inequalities in Neighborhood Walkability Drive Disparities in Older Adults' Outdoor Walking? *Int J Environ Res Public Health*. 2017 2017-07-07;14(7).
26. Jeffrey D, Boulangé C, Giles-Corti B, Washington S, Gunn L. Using walkability measures to identify train stations with the potential to become transit oriented developments located in walkable neighbourhoods. *J TRANSP GEOGR*. 2019 2019-01-01;76:221-31.
27. Creatore MI, Glazier RH, Moineddin R, Fazli GS, Johns A, Gozdyra P, et al. Association of Neighborhood Walkability With Change in Overweight, Obesity, and Diabetes. *JAMA*. 2016 2016-05-24;315(20):2211-20.
28. James P, Kioumourtoglou MA, Hart JE, Banay RF, Kloog I, Laden F. Interrelationships Between Walkability, Air Pollution, Greenness, and Body Mass Index. *EPIDEMIOLOGY*. 2017 2017-11-01;28(6):780-8.
29. Yu R, Cheung O, Lau K, Woo J. Associations between Perceived Neighborhood Walkability and Walking Time, Wellbeing, and Loneliness in Community-Dwelling Older Chinese People in

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

508 Hong Kong. *Int J Environ Res Public Health*. 2017 2017-10-09;14(10).

509 30. Brath H, Kim SJ, Savage RD, Bronskill SE, Rochon PA, Stall NM. Neighborhood Walkability of
510 Retirement Homes: A Cross-Sectional Cohort Study. *J AM MED DIR ASSOC*. 2019
511 2019-01-01;20(1):105-6.

512 31. WalkScore. Walk Score Methodology.; 2020.

513 32. Long Y. The Large-Scale Calculation of “WalkScore” of Main Cities in China. *New*
514 *Architecture*. 2018(3):4-8.

515 33. Tencent. Wechat official website.; 2020.

516 34. Tian W, Song J, Li Z, de Wilde P. Bootstrap techniques for sensitivity analysis and model
517 selection in building thermal performance analysis. *APPL ENERG*. 2014 2014-01-01;135:320-8.

518 35. Kim H, Choi Y, Ma J, Hyung K, Miyashita M, Lee S. The Neighborhood Environment
519 Walkability Scale for the Republic of Korea: Reliability and Relationship with Walking. *IRAN J*
520 *PUBLIC HEALTH*. 2016 2016-11-01;45(11):1427-35.

521 36. Adlakha D, Hipp JA, Brownson RC. Adaptation and Evaluation of the Neighborhood
522 Environment Walkability Scale in India (NEWS-India). *Int J Environ Res Public Health*. 2016
523 2016-04-02;13(4):401.

524 37. Messer LC, Jagai JS, Rappazzo KM, Lobdell DT. Construction of an environmental quality
525 index for public health research. *Environ Health*. 2014 2014-05-22;13(1):39.




Figure 1. Flow chart


506x378mm (72 x 72 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

AMU 1st Hospital







Questionnaire

Part One: Basic Personal Information

1. Name: _____

2. Physical Examination Number: _____

3. Birthplace: City _____, Province _____

4. Present Address: Number _____, Neighborhood Committee/Village _____,
Township/Street _____, District/County _____, City _____
Province _____

5. Work Address: Number _____, Neighborhood Committee/Village _____,
Township/Street _____, District/County _____, City _____
Province _____

6. Except for home and office, is there any other place you are frequently present?

☐ Yes ☐ No If yes, how long will you spend in this place in one week? ____ hours

7. ID Number: _____

8. Nationality: ☐ The Han Nationality ☐ National Minority: _____

9. Blood Type: _____

10. Height: _____ cm

11. Weight: _____ kg

12. Education Level:

☐ Did not attend school normally

☐ Primary school or below

☐ Junior high school

☐ High school and secondary technical school

☐ Junior college

☐ Undergraduate college

☐ Master degree and above

13. Category of Employment:

- ☐Company employee
- ☐House
- ☐Student
- ☐Active duty soldier
- ☐Freelancer
- ☐Industrial worker
- ☐Self-employed people
- ☐Full-time driver
- ☐Service and sales personnel
- ☐Professional and technical personnel
- ☐Civil servant, personnel of public institutions and state-owned enterprises
- ☐Farmers, herdsmen and fishermen
- ☐Others

14. Are you currently customer of Wechat daily step calculator?

- ☐Yes
- ☐No

15. In the past week, what is your average step recorded by Wechat daily step calculator, or other step recorder? _____steps

Part Two: Family History and Personal Health Status

1. Family History (Choose the diseases which your relatives are / were diagnosed with at present / in the past from those listed below)

Are / were your parents, brothers or sisters currently diagnosed with the following diseases?

(multiple choice, put a ✓ under the options)

Diseases	Father	Mother	Brother	Sister
Lung cancer				
Liver cancer				
Gastric cancer				
Esophageal cancer				
Colorectal cancer				
Thyroid cancer				
Prostate cancer				
Cervical cancer				
Endometrial cancer				
Ovarian cancer				
Breast cancer				
Diabetes mellitus				
Hypertension				
Obesity				
Gout (hyperuricemia)				
Hyperlipidemia				
Asthma				
Chronic obstructive pulmonary (chronic bronchitis, emphysema)				
Stroke				
Coronary heart disease or myocardial infarction				
Osteoporosis				
Mental disease				
Other diseases				
None				

2. Personal History of Diseases

Whether the following diseases are / were diagnosed? (multiple choice)

- ☐Lung cancer
- ☐Liver cancer
- ☐Gastric cancer
- ☐Esophageal cancer
- ☐Colorectal cancer
- ☐Thyroid cancer
- ☐Prostate cancer
- ☐Cervical cancer
- ☐Endometrial cancer
- ☐Ovarian cancer
- ☐Breast cancer
- ☐Diabetes
- ☐Hypertension
- ☐Hyperlipidemia
- ☐Stroke
- ☐Asthma
- ☐Osteoporosis
- ☐Fracture
- ☐Mental disorders
- ☐Neurasthenia
- ☐Gout (hyperuricemia)
- ☐Thyroid disease (thyroiditis, nodule)
- ☐Chronic cholecystitis and cholelithiasis
- ☐Gastritis or duodenal ulcer
- ☐Coronary heart disease or myocardial infarction
- ☐Prostatic disease (hyperplasia of prostate, hypertrophy)
- ☐Chronic obstructive pulmonary disease (chronic bronchitis, emphysema)
- ☐Chronic liver disease (☐hepatitis B, ☐hepatitis C, ☐fatty liver, ☐alcoholic liver, ☐liver cirrhosis)
- ☐Chronic glomerulonephritis (nephritis, nephrotic syndrome, chronic renal insufficiency)
- ☐Chronic breast diseases (hyperplasia of mammary glands, nodules, adenosis, cysts, etc.)
- ☐Chronic gynecologic diseases (uterine fibroids, ovarian cysts, inflammations, etc.)
- ☐History of operation: (The operation name:_____)
- ☐Other diseases
- ☐None of the above diseases

3. Medication History

Do you take the following medicines for a long term? (continuous use for above 6 months, and more than once per day on average)

- ☐Hypotensive drugs
- ☐Beta blockers
- ☐Psychotropic drugs
- ☐Antiarrhythmic drugs

- ☐ Uric acid-lowering drugs ☐ Hypoglycemic drugs
- ☐ Sedative or hypnotic drugs ☐ Hormone drugs
- ☐ Chinese herbal medicines ☐ Antipyretic analgesics
- ☐ Antiplatelet drugs such as aspirin ☐ Lipid-modulating drugs (lipid-lowering drugs)
- ☐ Angiotensin-converting enzyme inhibitors ☐ Anti-asthmatic drugs
- ☐ Others ☐ None

Part Three: Eating Habits and Lifestyle

1. Eating Habit

1.1. Generally speaking, how many days during a week will you eat the following food on average? (single choice)

Rice	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Noodles	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Coarse Cereals	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Meat (pigs, cattle, sheep, poultry)	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Fish or other aquatic products	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Fresh vegetable and fruit	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Milk and dairy products	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Eggs and their products	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Beans and bean products	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Dessert (pastries, candy, etc)	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Fried food	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Pickled, smoked food	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat

1.2. In the past year, did you take the following nutrients for at least one month?

(except for ginseng)

☐Cod liver oil / fish oil

☐Ginseng (at least five times a year)

☐Vitamin

☐Other health supplements

☐Calcium / iron / zinc

1.3. Have you ever experienced severe food shortages in your life?

☐Yes ☐No If not, please turn to question 4

1.3.1. In which year did you experience the most severe food shortage? _____

1.3.2. When you were experiencing the most severe food shortage:

1.3.2.1. Did your weight decrease significantly?

☐ Yes ☐ No If yes, it dropped by ____ kilograms

1.3.2.2. Did you suffer from edema, severe anemia and other diseases caused by food shortages such as? ☐ Yes ☐ No

1.4. In the past month, how often did you eat spicy food?

☐ Never / almost never ☐ 1-2 days a week

☐ A few times, but less than once a week on average

☐ 3-5 days a week ☐ Every day or almost every day

1.5. How old did you begin to eat spicy food every week? ____ years old

1.6. Do you like slightly spicy food or very spicy food?

☐ Slightly spicy ☐ Spicy ☐ Very spicy

1.7. Do you order food online?

☐ Yes ☐ No

1.8. How often will you order food online in one week? ____ Times

1.9. What are the categories of online-ordered food you select?

☐ Noodles with soup ☐ Rice ☐ Fried noodles ☐ Dumplings

☐ Sweet food, eg.cake ☐ Drinks ☐ Others

1.10. How often will you eat outside home (not including online order food)?
____ Times

2. Smoking

Do you smoke? <input type="checkbox"/> Yes. Please answer questions 2.1, 2.2, 2.5 and 2.6 <input type="checkbox"/> No. Please answer questions 2.7-2.8. <input type="checkbox"/> Quit smoking. (have quit smoking for more than one month) Please answer questions 2.3-2.6.	2.1. You began to smoke at the age of ____.
	2.2. You smoke ____ cigarettes per day on average.
	2.3. You quit smoking at the age of ____.
	2.4. Before quitting smoking, you smoked ____ cigarettes per day on average.
	2.5. Which type of cigarettes do you smoke at present/or did you smoke before quitting? <input type="checkbox"/> Filter cigarette <input type="checkbox"/> Non-filter Cigarettes <input type="checkbox"/> Cigar <input type="checkbox"/> Hand-rolled cigarette / tobacco <input type="checkbox"/> Tobacco pipe / waterpipe smoking
	2.6. Which organ do you suck the smoke into?

	<input type="checkbox"/> To the mouth and exhale it <input type="checkbox"/> To the pharynx and larynx <input type="checkbox"/> Deep to the lung-Have you kept the habit of sucking smoke into the lung ever since you began smoking? <input type="checkbox"/> Yes <input type="checkbox"/> No
	2.7. Have you ever been exposed to the second hand smoke? <input type="checkbox"/> Yes <input type="checkbox"/> No
	2.8. How many times have you been exposed to the second hand smoke? <input type="checkbox"/> Nearly everyday <input type="checkbox"/> 4-5 days a week <input type="checkbox"/> 1-3 days a week <input type="checkbox"/> ≤ 1 day per week

3. Alcohol drinking

3.1. Do you drink alcohol? (Make the choice and fill in the blanks based on reality)

- ☐ Never ☐ In the past (have quit drinking for more than 6 months)

☐ Yes (If yes, please answer questions 3.1.1-3.1.4)

3.1.1 You began to drink alcohol at the age of _____.

3.1.2 How often do you drink? (Single choice)

- ☐ Twice almost everyday ☒ Once almost everyday ☐ 3-4 times a week

- ☐ 1-2 times a week ☐ Drink every month, but less than once a week ☐ Seldom

3.1.3 How much do you drink each time (only fill in the blanks with the alcohol you drink commonly)?

- ☐ Beer, _____ bottles/day
- ☐ Yellow wine / rice wine / fruit wine, _____ grams/day
- ☐ Wine, _____ grams/day
- ☐ Liquor with a high alcohol level ($\geq 40^\circ$), _____ grams/day
- ☐ Liquor with a low alcohol level ($\leq 40^\circ$), _____ grams/day

4. Sleeping (Make the choice and fill in the blanks based on reality)

4.1. How is the quality of your sleep in the past month?

- ☐ Very good ☐ Good ☐ Bad ☐ Very bad

4.2. How long did you sleep per day on average in the past month? ____ hours

4.3. Did you need to take medicine to help you fall asleep in the past month?
(medicine prescribed by the doctor or purchased by yourself)

- ☐ No ☐ < Once every week on average
☐ Once-twice every week on average ☐ ≥ 3 times every week on average

5. Physical activity

5.1. In the past year, what is your activity status during work?

- ☐ Sedentary ☐ Standing ☐ Activity with medium amount
☐ Activity with heavy work load ☐ Retired or disabled to work

5.2. What is your average working hour in one week? _____ hours

5.3. In the past your, what is your transportation way to go to work?

- ☐ Walking ☐ Driving ☐ Taking a bus
☐ Riding a bike ☐ Work at home ☐ Others
or the place closed to home

5.4. How long is the commuting time of your work? _____ min

5.5. In the past one year, what is your physical activity frequency?

- ☐ Never ☐ 1-3 times one month ☐ 1-2 times one week
☐ 3 -5 times one week ☐ Almost everyday

5.6. What is the exercise way you did the most frequently?

- ☐ Taichi/Walking ☐ Fast walking ☐ Running/or other aerobics
☐ Swimming ☐ Ball game ☐ Others(such as hiking)

5.7. During the last 7 days, on how many days did you do vigorous physical activities like heavy lifting, digging, heavy construction, or climbing up stairs as part of your work?

_____ days per week

5.8. How much time did you usually spend on one of those days doing vigorous physical activities as part of your work?

_____ hours per day, _____ minutes per day

5.9. During the last 7 days, on how many days did you do moderate physical activities like carrying light loads as part of your work? Please do not include walking.

_____ days per week

5.10. How much time did you usually spend on one of those days doing moderate physical activities as part of your work?

_____ hours per day, _____ minutes per day

5.11. During the last 7 days, on how many days did you walk for at least 10 minutes at a time as part of your work?

_____ days per week

5.12. How much time did you usually spend on one of those days walking as part of your work?

_____ hours per day, _____ minutes per day

5.13. During the last 7 days, how much time did you usually spend sitting on a weekday?

_____ hours per day, _____ minutes per day

5.14. Did you use sport watch or app for record steps or heart rate?

☐Yes ☐ No

If yes, the name of sport watch is_____, the name of the sport app is_____

6. Others

6.1. Are you satisfied with your current living conditions?

☐Cannot be more satisfied ☐Basically satisfied
☐Ordinary ☐Dissatisfied ☐Very dissatisfied

6.2. Did you experience the events that have a significant impact on your life in the past two years, such as those listed below?

- | | |
|--|---|
| <input type="checkbox"/> Marital separation/divorce | <input type="checkbox"/> Serious trauma or car accident |
| <input type="checkbox"/> Unemployment / laid-off / retirement | <input type="checkbox"/> Death of spouse |
| <input type="checkbox"/> Serious family diversity and conflicts | <input type="checkbox"/> Violent attacks / rapes |
| <input type="checkbox"/> Loss of economic resources / liabilities | |
| <input type="checkbox"/> Bankruptcy of self-owned business or family economic breakdown | |
| <input type="checkbox"/> Death or serious diseases of other family members | |
| <input type="checkbox"/> Serious natural disasters (such as drought, waterlogging, etc.) | |
| <input type="checkbox"/> None | |

6.3. In the past year, are you under great mental stress in work and life?

☐No pressure ☐Little pressure ☐Ordinary

☐Great pressure ☐Extremely great pressure

6.4. In the past one year, is any change in your body weight?

☐No ☐Add at least 2.5kg ☐Lose at least 2.5kg

6.5. In the past one year, do you using drugs or controlling diet intake in order to lose weight?

☐Yes ☐No

6.6. Could you remember your body weight when you was at age of 25?

_____kg; ☐Not applicable

Signature_____

Variable category	Name of variable	Normal limits or categories	Definition of variable	Data resources
Primary Outcome	body mass index	18.5-24kg/m2	outcome	calculate from health examination information
	daily steps in one month		mediator and outcome	Wechat mini application
Secondary Outcome	fasting blood glucose (GLU)	3.6-6.1 (mmol/L)	outcome	health examination
	total cholesterol (TC)	3.1-5.7 (mmol/L)	outcome	health examination
	triglyceride (TG)	0.4-1.73 (mmol/L)	outcome	health examination
	low density lipoprotein cholesterin (LDL-C)	2.07-3.1 (mmol/L)	outcome	health examination
	high density lipoprotein cholesterin (HDL-C)	0.9-2 (mmol/L)	outcome	health examination
	body composition	mass percentage of fat	outcome	health examination
	height			health examination
Other variables	weight			health examination
	age	16 - 65 years old	possible confounding	questionnaire
	gender	male; female	possible confounding	questionnaire
	job		possible confounding	questionnaire
	education	under primary school; primary school, middle school; bachelor; master and above	possible confounding	questionnaire
	WalkScore corresponding to home address	0-100	exposure	calculate from questionnaire information
	WalkScore corresponding to workplace address	0-100	exposure	calculate from questionnaire information
	smoking status	giving up; never; sometimes smoke; frequently smoke	other factors will influence outcome	questionnaire
	alcohol consumption	giving up; never; sometimes drink; frequently drink	other factors will influence outcome	questionnaire
	online food order habit	never; sometimes order; frequently order	possible confounding	questionnaire
	eating diet	more details showed in questionnnaire	other factors will influence outcome	questionnaire
	physical activity	more details showed in questionnnaire	possible confounding	questionnaire

The name of health examination	Specific name of items	Normal limits or result categories
Five items of thyroid function	Free triiodothyronine (FT3)	2.0-6.6 pmol/L
	Free thyroxine (FT4)	10.3-31.9 pmol/L(0.8~2.3ng/dL)
	Thyroid-stimulating hormone (TSH)	0.3-4.5 uIU/mL
	Total triiodothyronine (TT3)	1.8-2.9 nmol/L(115~190ng/dL)
	Total thyroxine (TT4)	65-155 nmol/L(5.0~12.0µg/dL)
12-leads electrocardiogram		N=Normal; A=abnormal
Ultrasound (splenorenal major abdominal and portal vein)		
	Liver	N=Normal; A=abnormal
	Gallbladder	N=Normal; A=abnormal
	Pancreas	N=Normal; A=abnormal
	Spleen	N=Normal; A=abnormal
	Bilateral kidneys	N=Normal; A=abnormal
	Portal vein	N=Normal; A=abnormal
Carcinoembryonic antigen (CEA)		0-5 (ng/ml)
Liver function	Albumin (Alb)	38-51 (g/L)
	Albumin/Globulin	1.2-2.5
	Gamma-glutamyl transpeptidase (GGT)	4-50 (IU/L)
	Alanine amino transferase (ALT)	0-42 (IU/L)
	Aspartate amino transferase (AST)	0-42 (IU/L)
	Alkaline Phosphatase (ALP)	34-114 (IU/L)
	Globulin (G)	25-38 (g/L)
	Total protein (TP)	66-83 (g/L)
Alpha-fetoprotein (AFP)		0-20 (ng/ml)
Urine routine	Potential of hydrogen (PH)	4.6-8.0
	Urine leukocyte (LEU)	Negative or positive
	Specific gravity (SG)	1.003-1.03
	Bilirubin (BIL)	Negative or positive
	Urobilinogen (URO)	N=Normal; A=abnormal
	Urine protein (PRO)	Negative or positive
	Urine Casts	Negative or positive

	Urine erythrocyte (ERY)	Negative or positive
	Urine pus cells	Negative or positive
	Urine colour	Negative or positive
	Uroepithelial cell (U-Epc)	Negative or positive
	Urine sugar (U-GLU)	Negative or positive
	Urine ketone (KET)	Negative or positive
	Urine nitrite (NIT)	Negative or positive
	Urine transparency	Negative or positive
	Urinary mucous silk (U-MUCS)	Negative or positive
	Creatinine (CR)	45-84 (μmol/L)
	Blood urea nitrogen (UN)	1.7-8.3 (mmol/L)
	Uric acid (UN)	155-428 (μmol/L)
	Fasting blood glucose (GLU)	3.6-6.1 (mmol/L)
	Serum cystatin c (Cys-c)	0.5-1.1 (mg/L)
Blood routine		
	white blood cell (WBC)	3.5-9.5 (10 ⁹ /L)
	Percent monocytes (MON%)	3-10 (%)
	Monocytes (MON)	0.1-0.6 (10 ⁹ /L)
	Red blood cell (RBC)	3.8-5.1 (10 ¹² /L)
	Red blood cell distribution width (SD)	11-16 (%)
	Red blood cell distribution width (CV)	37-54 (%)
	Hematokrit (HCT)	35-45 (%)
	Percent lymphocyte (LYMPH%)	20-50 (%)
	Lymphocyte count (LYMPH)	1.1-3.2 (10 ⁹ /L)
	Mean corpuscular volume (MCV)	82-100 (fL)
	The average RBC hemoglobin content (MCH)	27-34 (pg)
	The average RBC hemoglobin concentration (MCHC)	316-354 (g/L)
	mean platelet volume (MPV)	9-13 (fL)
	Basophilic cell percentage (BAS%)	0-1 (%)
	absolute basophil count (BAS)	0-0.06 (10 ⁹ /L)

	Acidophilic cell percentage (EOS%)	0.4-8 (%)
	Acidophil number (EOS)	0.02-0.58 (10*9/L)
	Hemoglobin (HGB)	115-150
	Platelet distribution width (PDW)	9-17 (%)
	blood platelet count (PLT)	125-350 (10*9/L)
	Thrombocytocrit (PCT)	N (%)
	Neutrophilic granulocyte percentage (NEU%)	40-75 (%)
	Neutrophilic granulocyte count (NEU)	1.8-6.3 (10*9/L)
Blood lipid		
	Total cholesterol (TC)	3.1-5.7 (mmol/L)
	Triglyceride (TG)	0.4-1.73 (mmol/L)
	Low density lipoprotein cholesterol (LDL-C)	2.07-3.1 (mmol/L)
	High density lipoprotein cholesterol (HDL-C)	0.9-2 (mmol/L)
Two pairs of semi - hepatitis B		
	Hepatitis B e antibody (HBe)	Negative or positive
	Hepatitis B e antigen (HBeAg)	Negative or positive
	Hepatitis B surface antibody (HBs)	Negative or positive
	Hepatitis B surface antigen (HBsAg)	Negative or positive
	Hepatitis B core antibody (HBc)	Negative or positive
Ultrasound(bilateral mammary gland)		N=Normal; A=abnormal
Ultrasound(uterus, annex)		N=Normal; A=abnormal
Vaginal secretion examination	Trichomonad	Negative or positive
	Mycete	Negative or positive
	Cleanliness of leucorrhea	Negative or positive
Thinprep cytology test(TCT)		N=Normal; A=abnormal
Body composition		Mass percentage of fat, protein, and water

Supplementary Table 1. The timeline of study conduction

Approval of ethic committee	2018 July 10 th
Completion of clinical registration on Chinese Clinical Trial Registry Platform	2018 August 9 th
Date collection of demographic data and home/workplace addresses of participants	2019 October
Development of Wechat mini App for recording daily steps	2020 January
Previous data checking and data collection of questionnaire and health examination of participants	2020 March-May
Date collection of daily steps of participants by Wechat mini App	2020 June
Follow-up: Data collection of questionnaire, health examination of participants, and daily steps in one month	2020 December – 2021 February
Follow-up: Data collection of questionnaire, health examination of participants, and daily steps in one month	2021 December – 2022 February
Follow-up: Data collection of questionnaire, health examination of participants, and daily steps in one month	2022 December – 2023 February

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract P2 (b) Provide in the abstract an informative and balanced summary of what was done and what was found P2
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported P3
Objectives	3	State specific objectives, including any prespecified hypotheses P3
Methods		
Study design	4	Present key elements of study design early in the paper P5-P6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection P4-P7
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up P4-P5 <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed P6 <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable P4-P7
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group P6-P7
Bias	9	Describe any efforts to address potential sources of bias P6-P7
Study size	10	Explain how the study size was arrived at P6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why P7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding P7 (b) Describe any methods used to examine subgroups and interactions P7 (c) Explain how missing data were addressed P7 (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed P7 <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses P6

Continued on next page

Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount) P7
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18	Summarise key results with reference to study objectives
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias P7
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence P7
Generalisability	21	Discuss the generalisability (external validity) of the study results P7
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

The effects of walkability on physical activity and obesity: a prospective observational study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034882.R2
Article Type:	Protocol
Date Submitted by the Author:	23-Jun-2020
Complete List of Authors:	Zhang, Yalan; Third Military Medical University Southwest Hospital, Health Management Centre Chen, Siyu; Third Military Medical University Southwest Hospital, Department of Epidemiology and Biostatistics Shi, Jiayang; Third Military Medical University Southwest Hospital, Health Management Centre Chen, Zongtao; Third Military Medical University Southwest Hospital, Health Management Centre
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Epidemiology, Public health, Sports and exercise medicine
Keywords:	EPIDEMIOLOGY, SPORTS MEDICINE, CLINICAL PHYSIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

The effects of walkability on physical activity and obesity: a prospective observational study protocol

Yalan Zhang^{1¶}, Siyu Chen^{2¶}, Jiayang Shi¹, Zongtao Chen^{1*}

¹Health Management Centre, First Affiliated Hospital (Southwest Hospital), Army Medical University, Chongqing, P.R. China.

²Department of Epidemiology and Biostatistics, First Affiliated Hospital (Southwest Hospital), Army Medical University, Chongqing, P.R. China

*Corresponding author

E-mail: chenzongtao@126.com

¶These authors contributed equally to this work.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction

The prevalence of overweight and obesity is increasing worldwide, which could lead to a set of chronic and metabolic diseases. Physical activity is a modifiable factor for obesity, which was reported to be correlated with built environment. However, the effects of built environment on physical activity are not consistent. Walkability is a convenient way to assess built environment. We aim to prospectively explore the relationship among walkability, physical activity, and obesity in Chinese participants in Chongqing, and provide evidence for future urban planning.

Methods and analysis

Participants will be recruited from people who receive health examination in the Health Management Centre, the First Affiliated Hospital to Army Medical University. Exposure variables are WalkScores calculated within the areas around workplace and residential addresses of participants. The primary outcomes are body mass index (BMI) measured through health examination at baseline and daily walking steps recoded by WeChat mini application for 30 days at follow-ups. Other health-related data of the participants will also be collected. Multivariate regression analysis will be performed to examine the relationship between exposure variables and outcomes.

Ethics and dissemination

The Protocol is approved by the Ethics Committee of the First Affiliated Hospital to Army Medical University (KY201839). The results will be actively disseminated through peer-review journals and conference publications.

Strengths and limitations of this study

- This study innovatively evaluates the effects of walkability on physical activity and obesity in a hilly city.
- The daily walking steps were recorded by a novel method --- WeChat mini application.
- This combines the data collected from health examination and cellphones.
- One limitation is it would fail to record data during swimming and other physical activities.
- The other limitation is the maximum time for data collection is 30 days after one authorization.

Introduction

The prevalence of overweight and obesity has doubled worldwide since 1980, which is currently 5% in children and 12% in adults.¹ In 2015, the number of children and adults who suffered from obesity was 107.7 million and 603.7 million, respectively.² High body mass index (BMI), an indicator for obesity, was identified to be a risk factor for various chronic diseases, including cardiovascular disease, diabetes, chronic kidney disease, and cancers.² Chinese Health and Nutrition Survey showed the rate of obesity and overweight in adults increased from 25.1% to 39.6% from 1997 to 2009.³ The updated prevalence of overweight and obesity were reported to be 25.8% and 7.9%, respectively, in 2017.⁴ It is reported that the obesity rate in Chongqing in Southwestern China is 10.3%.^{5, 6}

One of the modifiable risk factors of obesity and chronic diseases is physical inactivity.⁷⁻⁸ Physical inactivity is partly due to insufficient activity during leisure time and an increase in sedentary behavior during occupational and domestic activities.⁹ Additionally, an increase in the use of "passive" modes of transport has also been associated with declining physical activity levels, which means less walking or any human powered movement in daily life.⁹ Insufficient physical activity contributes to 6% of the disease burden of coronary heart disease, 7% of that of type 2 diabetes, 10% of that of breast cancer, and 10% of that of colon cancer.¹⁰ As reported, more than 533,000 deaths and more than 1.3 million deaths could be averted annually by reducing the prevalence of physical inactivity by 10% and 25%, respectively.¹⁰ Thus, in order to ameliorate physical inactivity, it is crucial to understand its associated factors and determinants. The factors associated with physical activity in high-income countries were reported to be age, sex, health status, self-efficacy, genetic factors, and motivation.¹¹ At the level of population, the factors outside health sectors have been identified to be causally related to physical inactivity, for example, urban planning, transportation system, and built environment.¹¹⁻¹³

Walkability is a useful tool in the process of evaluating the effects of the built environment on physical activity.¹⁴ However, there have been inconsistency with respect to built environment, walkability, physical activity, and health. A study published in *Nature* in 2017 with more than 700 thousand participants and 68 million days recorded revealed that higher walkability was associated with more daily walking steps, whose effect was stronger for females.¹⁴ Porter and colleagues also indicated in a cohort study with 688 participants that as one aspect of the neighborhood environment, walkability was associated with physical activity among pregnant women.¹⁵ Other studies from Japan and North America also supported the positive effects of built environment on physical activity.¹⁶⁻¹⁸ In a middle size city Bengbu in Eastern China, researchers observed about at least 30% lower risk of cardiovascular diseases were associated with moderate to high levels of WalkScore, compared with controls with low WalkScore, in which WalkScore is a measure of walkability.¹⁹ However, a cohort study with 1819 households investigating moving to the former Olympic athletes' village in London discovered no effect associated with this living environment change on daily walking steps, indicating that ameliorating the built environment might be insufficient to enhance physical activity.²⁰ A study with 161 older adult participants in Canada also showed that walkability was not associated with physical activity volume or intensity.²¹ A study in a small city in China called Yuncheng also

showed no positive associations of land-use mix and walking duration.²² In addition to these inconsistent evidence, there is no research of walkability effects on physical activity and health in China.

The factors of walkability usually include residential housing units, retail shops, public transportation, street-level movement density, the distance to behavior-related destinations.²³ Residential housing units are a house, apartment, group of rooms, or a single room for occupancy as a separate living unit, which could predict the population allocation in an area.²⁴ Retail shops are one kind of points of interest, which serve for non-residential uses and can enhance the motivation of walking.²⁵ Street accessibility, which are represented by the street-level movement density and the distance to behavior-related destinations, as well as the proximate access to public transportation are crucial characteristics of a walkable neighborhood.²⁶ Some studies also take into account the population density, the street connectivity, land-use diversity, infrastructure and safety for walking, aesthetics, and crime influence.²⁷⁻²⁹ WalkScore (www.WalkScore.com) is a user-friendly open composite walkability index. It could evaluate the walkability of a mail address or a city and is widely used in the studies investigating the relationship between walkability and health status.^{14, 30}

The evaluation of the walkability of a community and its effects on physical activity and health status of the residents in China could shed a light on urban design, laying a foundation for future urban planning policy and physical activity promotion interventions. Additionally, there is a gap of research on the influences of walkability on the physical activity in a hilly city. This protocol is an observational, prospective cohort study of participants who receive physical examination in the First Affiliated Hospital to Army Medical University. The aim of this study is to analyze the relationships among walkability, physical activity, and obesity in the residents in Chongqing for future urban planning reference. A map and photos with the hilly topography of Chongqing are showed in Supplementary Figure 1. Our research hypothesis is that high WalkScore will be associated with the decrease of BMI. The daily walking steps and metabolic profiles will be the mediators through the effect pathway from WalkScore to BMI. We illustrate our hypothesis of causal diagram in Supplementary Figure 2.

Materials and Methods

Study design and setting

The location of our protocol is Chongqing, a Chinese city, with multi-commercial centres, which is characterized by a unique hilly topology with two rivers, Yangtze and Jialing.³¹ Blood samples, clinical data, addresses, and related variables are collected prospectively from participants who receive physical examination in the Health Management Centre, First Affiliated Hospital to Army Medical University, Chongqing. Clinical and demographic data are recorded in the hospital's database. The daily walking steps of participants are collected by WeChat mini application. Blood samples are examined by the clinical laboratory of the hospital. The addresses and the part of listed variables in Table 1 will be collected by a questionnaire referred to a comprehensive cohort study named China Kadoorie Biobank study.³² Participants will be recruited from October

2019 to 2020 and followed up till 2023. The recruitment period will be extended if necessary. Moreover, we will include the participants who had pre-existing appointment if he/she meets the inclusion/exclusion criteria. We need to require this kind of participants to provide home and workplace addresses on the first visit and fill questionnaire on the second visit after recruitment. The recruitment process can be referred to Figure 1.

For peer review only

176 Table 1. All measured variables.

Variable category	Name of variable	Normal limits* or categories	Definition of variables	Sources of data
Primary outcomes	Body mass index	18.5-24kg/m2	Outcome	Calculate from health examination data
	Daily walking steps in one month		Outcome and mediator	Wechat mini application
Secondary outcomes	Fasting blood glucose (GLU)	3.6-6.1 (mmol/L)	Outcome	Health examination
	Total cholesterol (TC)	3.1-5.7 (mmol/L)	Outcome	Health examination
	Triglyceride (Tg)	0.4-1.73 (mmol/L)	Outcome	Health examination
	Low density lipoprotein cholesterin (LDL-C)	2.07-3.1 (mmol/L)	Outcome	Health examination
	High density lipoprotein cholesterin (HDL-C)	0.9-2 (mmol/L)	Outcome	Health examination
	Body composition	Mass percentage of fat	Outcome	Health examination
Exposure variables	WalkScore corresponding to home address	0-100	Exposure	Calculate from questionnaire information
	WalkScore corresponding to workplace address	0-100	Exposure	Calculate from questionnaire information
Other variables	Height			Health examination
	Weight			Health examination
	Age	16 - 65 years old	Possible confounding	Questionnaire
	Gender	Male; female	Possible confounding	Questionnaire
	Job		Possible confounding	Questionnaire
	Education	Under primary school;	Possible confounding	Questionnaire

		primary school, middle school; bachelor; master and above	
	Smoking status	Giving up; never; Other factors will influence sometimes smoke; outcome frequently smoke	Questionnaire
	Alcohol consumption	Giving up; never; Other factors will influence sometimes drink; outcome frequently drink	Questionnaire
	Online food order habit	Never; sometimes order; Possible confounding frequently order	Questionnaire
	Eating diet	More details showed in questionnaire Other factors will influence outcome	Questionnaire
	Physical activity	More details showed in questionnaire Possible confounding	Questionnaire

*“Normal limits” means in these limits, the corresponding condition is normal, otherwise it suggests there may be some health concerns or some errors.

Participants

This is an open cohort study. Participants are eligible for inclusion if they satisfy the following criteria: an age between 16 and 65, using smart phones, habitual residents in the downtown area of Chongqing.

The exclusion criteria will be: 1. participants with the symptoms or signs of cardiovascular and cerebrovascular diseases, such as chest tightness, shortness of breath, and even chest pain, especially those whose symptoms get worse when climbing stairs or walking fast; 2. participants with diagnosed heart diseases, such as coronary heart diseases, hypertensive heart diseases, valvular heart diseases, and pulmonary heart diseases, who need to exercise based on principles of cardiac rehabilitation; 3. participants with other severe complications of diabetes, such as those with vision severely affected by eye diseases, those with balancing ability affected by peripheral neuropathy, those with diabetic foot, and those with renal dysfunction; 4. participants whose movement is affected by musculoskeletal disorders, e.g. patients with musculoskeletal disorders and cardiopulmonary dysfunction; 5. participants who refuse to provide corresponding information, or are not able to complete the questionnaire and health examination; 6. participants who plan to migrate to other areas or leave for a long time (more than one year); 7. participants with secondary morbid obesity caused by congenital diseases, metabolic diseases, neurologic diseases and endocrine diseases. Participant inclusion and follow-up will be checked by the health managers and nurses in the Health Management Centre. Participants must be able to sign written informed consent after acknowledging the benefits and risks of this study.

The number of the sample size was calculated using the following formula:

$$n = \frac{\left(z_{\alpha} \sqrt{2pq} + z_{\beta} \sqrt{p_0 q_0 + p_1 q_1}\right)^2}{\left(p_1 - p_0\right)^2}$$

The parameters used in the calculation are: p_0 (the obesity prevalence in control group) as 10.3%,⁶ the supposed risk ratio (RR) between groups with high WalkScore and low WalkScore as 0.5, $\alpha = 0.05$, and $1 - \beta = 0.9$. In this formula, $p_1 = p_0 * RR = 5.15\%$, $\bar{p} = (p_0 + p_1) / 2$, $\bar{q} = 1 - \bar{p}$, $q_0 = 1 - p_0$, and $q_1 = 1 - p_1$, $Z_{\alpha} = 1.96$, and $Z_{\beta} = 1.282$. Based on these parameters, the sample size in exposure group and control group should be 400, respectively. Concerning the possibility of loss of follow-up, we increased the sample size by 10% to 440 participants in each group. The final sample size is 880 in total.

Clinical data

The questionnaire filled by participants under nurses' guidance includes the questions of participant demographics, exposure, and lifestyle factors. We attached the full version of the questionnaire in Supplementary File 1. The measured variables, primary outcome, and secondary

outcomes, exposure variables, as well as possible confoundings are listed in Table 1. The variables in detail are showed in Supplementary File 2. The relationships among different variables are illustrated in a causal diagram in Supplementary Figure 2.

During the process of recruitment, the following data were collected by the questionnaire and health examination procedure as well as Wechat mini application:

1. Primary outcomes: Body mass index (BMI), and everyday walking steps are recorded by a WeChat mini application. Every year, the daily walking steps in 30 days will be collected after physical examination in the hospital. BMI was calculated by the weight in kilograms divided by the square of the height in meters. Overweight and obesity were defined as a BMI of 24–27.9 kg/m² and a BMI \geq 28 kg/m², respectively.⁴ The participants will authorize the application in order to allow the researchers in this study to obtain the daily walking steps in 30 days collected by the WeChat mini application.
2. Secondary outcomes: metabolic profiles by blood tests; for example, cholesterol levels and blood glucose. Body composition was measured by a machine named inbody 220, when doing the measurement in which, the participants will stand on the machine without shoes and hold the two poles of the machine for five minutes.
3. Exposure variables: Walkscores which will be calculated based on the workplace address and residential address of the participants.
4. Participant demographics: age, gender, height, marital status, and education.
5. Lifestyle factors: smoking status, alcohol consumption, online food order habit, eating diet, and physical activity
6. Identification of non-communicable diseases: e.g. hypertension, coronary artery disease, and diabetes.

Biological samples and assay methods

The blood samples are collected by nurses in the Health Management Centre in the morning. The participants should be fasting for 12 to 14 hours before health examination. A sum of 5mL blood was collected in the yellow tube with inert separating gel for cholesterol and glucose testing. A total of 2mL blood for blood routine test was stored in a purple tube with ethylenediaminetetraacetic acid (EDTA) as anticoagulant. The blood samples are analyzed by automated biochemical analyzer, with the series number of Beckman AU5811. Total cholesterol was tested by the cholesteroxidase (CHO) enzyme method. Triglyceride was tested by the glycerol phosphate dehydrogenase and peroxidase (GPO-POD) method.

Physical examination

The physical examination included the measurement of height, body weight, blood pressure, and body component following the guidelines of the Health Management Centre. The blood pressure was evaluated by electronic sphygmomanometer (Omron, type : B-203RV III C). The machine Inbody 220 was used to analyze body component.

WalkScore

WalkScore measures pedestrian friendliness by analyzing the distance to points of interest and the weights of points of interest. Data sources are from Google, Factual, Great Schools, Open Street Map, the U.S. Census, Localeze, and places added by the Walk Score user community.³³ The algorithm of WalkScore is not disclosed in its official website. The formula³⁴ of WalkScore illustrated in Tsinghua University is

$$\sum_{i=1, j=1}^{m,n} (W_i * S_{i,j} * D_{i,j}) * \frac{100}{15}$$

W_i is the weight of one kind of amenity. Table 2 shows the weights of different amenities.

Amenity category	Weight	Amenity category	Weight	Amenity category	Weight
convenience store	3	café/teahouse	2	school	1
restaurant	3	bank	1	bookstore	1
shop	2	park	1	entertainment places	1

Table 2. Weights of different amenities.

The letter of i stands for different kinds of amenities. The letter of j stands for different walking distance. S_{i,j} stands for service scope of a specific amenity. D_{i,j} stands for the attenuation coefficient based on distance from the calculated point to an amenity. Table 3 shows the attenuation coefficients based on the distances from the calculated point to an amenity.

Distances	Attenuation coefficients
<400 metres	1
400-800 metres	0.9
800-1200 metres	0.55
1200-1600 metres	0.25
1600-2400 metres	0.08
>2400 metres	Out of scope, which will not be calculated.

Table 3. Attenuation coefficients based on the distances.

The calculation of WalkScore is free, to obtain which we could type the name of calculated point into the official website and wait for the score. The limit of the score is 0-100. The WalkScore of residential address and workplace address will be calculated separately.

The following Table 4 describes the meanings of different WalkScore.

WalkScore	Description
90 - 100	Walker’s Paradise: Daily errands do not require a car.

70 - 89	Very Walkable: Most errands can be accomplished on foot.
50 - 69	Somewhat Walkable: Some errands can be accomplished on foot.
25 - 49	Car-dependent: Most errands require a car.
0 - 24	Almost all errands require a car.

Table 4. Interpretations of different WalkScore.

Wechat mini application

Wechat is a cellphone application for communication used by more than a billion people.³⁵ The customers of it can send voice, video, photos, and text. On the basis of Wechat and its great number of users, the company of Wechat opens the resources to the public of developing different kinds of Wechat mini applications. Users could link its Wechat ID to Wechat mini application without download installment package and achieve data sharing through Wechat mini application. Wechat could also extract daily step data from users' cellphones after user's agreement. Through Wechat mini application, we could extract the daily walking steps of Wechat users in one month after customer agreement. After we develop the Wechat mini application following the guideline from Wechat and publish it, the participants could open the Wechat mini application in their Wechat and signed a consent to agree that they are willing to allow us extract daily steps. Then, the customers' daily step information will be delivered to our datasets automatically. The obtained data will be consistently with the records in participants' cell phones.

Statistical methods

The data analysis will be conducted after data collection in 2020. The prospective analysis will be implemented in 2023. Descriptive statistics is performed to analyze the distribution of the data. Missing data were addressed by deletion or last observation carried forward based on specific case status. Single variable analysis will be implemented to analyze the correlations between exposures, possible confoundings (i.e., online food order habit, education, job, physical activity), and outcomes. The participants will be divided into five groups by the categories of the WalkScore with regard to workplace address and residential address, respectively. The lifestyle factors and outcomes will be compared among groups. All the variables in causal diagrams will be compared between baseline and follow-ups. T-test will be used for the continuous variables, and Chi-square test or Analysis of Variance (ANOVA) will be used for categorical variables. Multivariate linear regression will be conducted taken BMI and daily walking steps as dependent variables, respectively, as cross-sectional analyses, after data collection in 2020. Further longitudinal analyses with G estimation and inverse probability weight analysis will be conducted after data collection in 2023 in order to take into account the effects of confounders whose conditions may change over time. Sensitivity analysis will be implemented by bootstrap method. With replacement from the original dataset, the bootstrap method enables estimation of the accuracy of an estimator by random sampling. The first step is to determine the ranges and variations of the independent variables, which are input into our multivariate linear regression.

The second step is to generate independent variables based on the Sobol sequence by R package “randtoolbox”. The final step is to collect and process the simulation results, which can be used in sensitivity analysis through conducting multivariate linear regression.³⁶

Patient and public involvement

Our study is an observational study without intervention on participants. The development of the research question and outcome measures were informed by participants’ priorities, experience, and preferences on the basis of informed consents. There is no participants’ involvement in the study design. We recruit participants when conducting the study, but participants would not be the conductor of the study. The results are planned to disseminate to study participants.

Ethics and dissemination

The Protocol is approved by the Ethics Committee of the First Affiliated Hospital to Army Medical University (KY201839). All the participants will receive consultation about the benefits and possible risks of the study from health managers and nurses, and endow written informed consent before enrollment. All the participants will be informed that they can withdraw from the study at any time for any reason. The withdrawal cases will be discarded and related information will be deleted from the database of the study.

The sample volume of blood for the study is 11 per participant-visit and maximum 55 for five years. The blood sampling process is part of the procedure of physical examination and this study acquires the data use authority after the recruitment. The participants will be contacted and informed the results of the physical examination. The researchers of this study will be responsible for implementing the study adhering to the Declaration of Helsinki.

We plan to analyze and publish study results according to the STROBE guidelines. Results will be published in international and peer-reviewed scientific journals. Negative, positive, conclusive or inconclusive results will be published.

Study Status

We collected demographic data, home addresses, and workplace addresses of participants in October 2019. We plan to check previous data and collect the data of health examination and questionnaire of participants in March to May 2020 and daily walking steps of participants by Wechat mini application in 2020 (in one month after health examination). We will continue follow-up in 2021-2023. The follow-up will be sustained by contacting with participants and requiring body examination by phone. Currently, the daily walking steps collector of the WeChat mini application has been developed. The study was registered in Chinese Clinical Trial Registry (ChiCTR) and the registration number is ChiCTR1800017680. The date of the study in a timeline is showed in Supplementary Table 1. There will be six waves of date collection.

Discussion and potential limitations

This observational and prospective study could innovatively provide evidence of the relationship among walkability, obesity, and physical activity in China. It will also provide evidence of the influence of built environment on physical activity in a hilly city, Chongqing. We hypothesized that the walkability, physical activity, and obesity status are strongly associated with each other. The use of WeChat mini application in data collection process have a lot of advantages. Through extracting data from cellphones' records, the data collection is very convenient and cost-effective which eliminates the errors of manual typing. The participants will sign informed consents before recruitment and sign an agreement to endow Wechat mini application to collect their daily steps before the use of Wechat, in which way we could ensure the process meets the ethic requirements.

There are some limitations in the collection of physical activity. The WeChat mini application can only record the daily walking steps when the participants walk with their phone. Like other studies, activities without carrying phones such as swimming and ball games will not be recorded in the data collection procedure.¹⁴ Moreover, more than 30 days' collection needs second authorization (the maximum data collection time is 30 days after one authorization) which is less adherent; thus the researchers could only collect the data of 30 days for convenience. In order to compensate for this limitation, the participants will be recruited all year round and the researchers will ask for a second authorization of daily step collection in the follow-up visit. In terms of season, the season when we do the data collection may also influence the number of daily steps. We will consider season as a confounder in future data analysis.

Moreover, WalkScore is based on an online calculation website which has not opened the algorithm officially. Other walkability evaluation tools such as Pedestrian Environment Quality Index (PEQI) depend on the evaluation of geographic information system (GIS), the score process of which is relatively clean; however, the practice is more complex.³⁷⁻³⁹ Thus, we decide to choose WalkScore for the primary analysis. If the results could indicate the relationship between walkability and obesity, we could further analyze the component factors of walkability in following analysis.

Legends

Figure 1. Flow chart of study.

Supplementary Figure 1A. Chongqing map.

It is the nine main districts of Chongqing extracted from Open Street Map. The black point shows the location of the First Affiliated Hospital to Army Medical University in Shapingba District. Shapingba District is an old town with a lot of renowned high schools and universities.

Supplementary Figure 1B. Chongqing location.

It shows the location of Chongqing relative to the other cities (Chengdu, Suining, Zigong, Jianyang, and so on). The topography of Chongqing is more hilly than that of Chengdu.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

407
408 Supplementary Figure 2. Causal diagram of measured variables.
409 Obesity and overweight is the primary outcome. WalkScore is the exposure variable. The
410 participants will be divided into five groups by the categories of the WalkScore with regard to
411 workplace address and residential address, respectively (In this way, we decide the exposure
412 degree). Daily walking steps and metabolic profiles are the mediator from WalkScore to obesity.
413 Job and education are possible confoundings between WalkScore and daily walking steps.
414 Physical activity and mental health scores are possible confoundings between daily walking steps
415 and metabolic profiles. Online food order habit is possible confounding between WalkScore and
416 metabolic profiles. Eating habit, smoking, and alcohol consumption are other factors, which will
417 influence metabolic profiles.
418
419 Supplementary Table 1. Timeline of study conduction.
420
421 **Funding:** there is no funding.
422
423 **Acknowledgements:** Thanks to Dr. Zhizhong Gong and Dr. Baoqi Fan for their suggestions of this
424 study. Thanks to patient/participant advisors in the Health Management Centre for their
425 assistance. Thanks to SC's friends Ms. Sarah Higbee-Tindell, Ms. Chu Yu, and Ms. Qingya Wu for
426 writing assistance of grammar modification.
427 .
428
429 **Competing interests:** All authors have completed the ICMJE uniform disclosure form at
430 http://www.icmje.org/coi_disclosure.pdf and declare: no support from any organization for the
431 submitted work; no financial relationships with any organization that might have an interest in
432 the submitted work in the previous three years, no other relationships or activities that could
433 appear to have influenced the submitted work.
434
435 **Contributors:** SC and YZ are joint first authors. SC contributed to study concept and design. SC
436 wrote the first draft of the protocol manuscript. ZC supervised the process. YZ and JS revised the
437 manuscript after feedback from all authors. YZ coordinates the conducting of this study. All
438 authors reviewed the manuscript and approved the final version of the manuscript.
439
440 **Data sharing statement:** No additional data are available.
441
442 **Patient consent:** Consent will be obtained in the enrollment process.
443
444 **Ethics approval:** The Protocol is approved by the Ethics Committee of the first affiliated hospital
445 to Army Medical University (KY201839).
446
447
448

449

450

References

1. E. W. Gregg, J. E. Shaw. Global Health Effects of Overweight and Obesity. *N Engl J Med* 2017;377(1):80-81. doi: 10.1056/NEJMe1706095 pmid:286042262017-07-06].
2. A. Afshin, M. H. Forouzanfar, M. B. Reitsma, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. *N Engl J Med* 2017;377(1):13-27. doi: 10.1056/NEJMoa1614362 pmid:286041692017-07-06].
3. Y. F. Wang, M. X. Sun, H. Xue, et al. [Understanding the China Blue Paper on Obesity Prevention and Control and policy implications and recommendations for obesity prevention and control in China]. *Zhonghua Yu Fang Yi Xue Za Zhi* 2019;53(9):875-84. doi: 10.3760/cma.j.issn.0253-9624.2019.09.003 pmid:314740672019-09-06].
4. L. Hu, X. Huang, C. You, et al. Prevalence of overweight, obesity, abdominal obesity and obesity-related risk factors in southern China. *PLOS ONE* 2017;12(9):e183934. doi: 10.1371/journal.pone.0183934 pmid:289103012017-01-20].
5. Y. Wang, J. Mi, X. Y. Shan, Q. J. Wang, K. Y. Ge. Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China. *Int J Obes (Lond)* 2007;31(1):177-88. doi: 10.1038/sj.ijo.0803354 pmid:166521282007-01-01].
6. Shuping Z. Changes in prevalence of overweight and obesity in a community in Chongqing from 2003 - 2013. *Chongqing Medicine* 2017;29(46):4108.
7. S. Stringhini, C. Carmeli, M. Jokela, et al. Socioeconomic status and the 25 x 25 risk factors as determinants of premature mortality: a multicohort study and meta-analysis of 1.7 million men and women. *LANCET* 2017;389(10075):1229-37. doi: 10.1016/S0140-6736(16)32380-7 pmid:28159391.[Copyright (c) 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. Published by Elsevier Ltd.. All rights reserved.:*2017-03-25].
8. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *LANCET* 2016;388(10053):1659-724. doi: 10.1016/S0140-6736(16)31679-8 pmid:27733284.[Copyright (c) 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. Published by Elsevier Ltd.. All rights reserved.:*2016-10-08].
9. World Health Organization. Physical Inactivity: A Global Public Health Problem. In, 2019.
10. I. M. Lee, E. J. Shiroma, F. Lobelo, et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. *LANCET* 2012;380(9838):219-29. doi: 10.1016/S0140-6736(12)61031-9 pmid:228189362012-07-21].
11. A. E. Bauman, R. S. Reis, J. F. Sallis, et al. Correlates of physical activity: why are some people physically active and others not? *LANCET* 2012;380(9838):258-71. doi: 10.1016/S0140-6736(12)60735-1 pmid:228189382012-07-21].
12. J. F. Sallis, E. Cerin, T. L. Conway, et al. Physical activity in relation to urban environments in 14 cities worldwide: a cross-sectional study. *LANCET* 2016;387(10034):2207-17. doi: 10.1016/S0140-6736(15)01284-2 pmid:27045735.[Copyright (c) 2016 Elsevier Ltd. All rights

reserved.:*2016-05-28].

13. M. Karineniemi, T. Lankila, T. Ikaheimo, H. Koivumaa-Honkanen, R. Korpelainen. The Built Environment as a Determinant of Physical Activity: A Systematic Review of Longitudinal Studies and Natural Experiments. *ANN BEHAV MED* 2018;52(3):239-51. doi: 10.1093/abm/kax043 pmid:295386642018-02-17].

14. T. Althoff, R. Sosis, J. L. Hicks, et al. Large-scale physical activity data reveal worldwide activity inequality. *NATURE* 2017;547(7663):336-39. doi: 10.1038/nature23018 pmid:286930342017-07-20].

15. A. K. Porter, D. A. Rodriguez, B. G. Frizzelle, K. R. Evenson. The Association between Neighborhood Environments and Physical Activity from Pregnancy to Postpartum: a Prospective Cohort Study. *J URBAN HEALTH* 2019;96(5):703-19. doi: 10.1007/s11524-019-00376-y pmid:313424032019-10-01].

16. R. Murillo, L. M. Reesor, D. C. Hernandez, E. M. Obasi. Neighborhood Walkability and Aerobic Physical Activity among Latinos. *AM J HEALTH BEHAV* 2019;43(4):802-11. doi: 10.5993/AJHB.43.4.13 pmid:312390222019-07-01].

17. R. Larouche, S. Blanchette, G. Faulkner, et al. Correlates of Children's Physical Activity: A Canadian Multisite Study. *Med Sci Sports Exerc* 2019;51(12):2482-90. doi: 10.1249/MSS.0000000000002089 pmid:313063032019-12-01].

18. S. Amagasa, S. Inoue, N. Fukushima, et al. Associations of neighborhood walkability with intensity- and bout-specific physical activity and sedentary behavior of older adults in Japan. *GERIATR GERONTOL INT* 2019;19(9):861-67. doi: 10.1111/ggi.13730 pmid:31290251.[(c) 2019 Japan Geriatrics Society.:*2019-09-01].

19. X. Jia, Y. Yu, W. Xia, et al. Cardiovascular diseases in middle aged and older adults in China: the joint effects and mediation of different types of physical exercise and neighborhood greenness and walkability. *ENVIRON RES* 2018;167:175-83. doi: 10.1016/j.envres.2018.07.003 pmid:30029039.[Copyright (c) 2018 Elsevier Inc. All rights reserved.:*2018-11-01].

20. C. M. Nightingale, E. S. Limb, B. Ram, et al. The effect of moving to East Village, the former London 2012 Olympic and Paralympic Games Athletes' Village, on physical activity and adiposity (ENABLE London): a cohort study. *Lancet Public Health* 2019;4(8):e421-30. doi: 10.1016/S2468-2667(19)30133-1 pmid:31345752.[Copyright (c) 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.:*2019-08-01].

21. A. M. Chudyk, H. A. McKay, M. Winters, J. Sims-Gould, M. C. Ashe. Neighborhood walkability, physical activity, and walking for transportation: A cross-sectional study of older adults living on low income. *BMC GERIATR* 2017;17(1):82. doi: 10.1186/s12877-017-0469-5 pmid:283956722017-04-10].

22. Z. Sun, K. Y. Lai, S. Bell, I. Scott, X. Zhang. Exploring the Associations of Walking Behavior with Neighborhood Environments by Different Life Stages: A Cross-Sectional Study in a Smaller Chinese City. *Int J Environ Res Public Health* 2019;17(1) doi: 10.3390/ijerph17010237 pmid:319056932019-12-28].

23. C. Sarkar, C. Webster, J. Gallacher. Neighbourhood walkability and incidence of hypertension: Findings from the study of 429,334 UK Biobank participants. *Int J Hyg Environ Health* 2018;221(3):458-68. doi: 10.1016/j.ijheh.2018.01.009 pmid:29398408.[Copyright (c) 2018 Elsevier GmbH. All rights reserved.:*2018-04-01].

24. D. R. Michanowicz, S. R. Williams, J. J. Buonocore, et al. Population allocation at the housing unit level: estimates around underground natural gas storage wells in PA, OH, NY, WV, MI, and CA. *Environ Health* 2019;18(1):58. doi: 10.1186/s12940-019-0497-z pmid:312807232019-07-08].
25. R. Zandieh, J. Flacke, J. Martinez, P. Jones, M. van Maarseveen. Do Inequalities in Neighborhood Walkability Drive Disparities in Older Adults' Outdoor Walking? *Int J Environ Res Public Health* 2017;14(7) doi: 10.3390/ijerph14070740 pmid:286862192017-07-07].
26. Dana Jeffrey, Claire Boulangé, Billie Giles-Corti, Simon Washington, Lucy Gunn. Using walkability measures to identify train stations with the potential to become transit oriented developments located in walkable neighbourhoods. *J TRANSP GEOGR* 2019;76:221-31. doi: <https://doi.org/10.1016/j.jtrangeo.2019.03.009>2019-01-01].
27. M. I. Creatore, R. H. Glazier, R. Moineddin, et al. Association of Neighborhood Walkability With Change in Overweight, Obesity, and Diabetes. *JAMA* 2016;315(20):2211-20. doi: 10.1001/jama.2016.5898 pmid:272186302016-05-24].
28. P. James, M. A. Kioumourtzoglou, J. E. Hart, et al. Interrelationships Between Walkability, Air Pollution, Greenness, and Body Mass Index. *EPIDEMIOLOGY* 2017;28(6):780-88. doi: 10.1097/EDE.0000000000000724 pmid:287675142017-11-01].
29. R. Yu, O. Cheung, K. Lau, J. Woo. Associations between Perceived Neighborhood Walkability and Walking Time, Wellbeing, and Loneliness in Community-Dwelling Older Chinese People in Hong Kong. *Int J Environ Res Public Health* 2017;14(10) doi: 10.3390/ijerph14101199 pmid:289912052017-10-09].
30. H. Brath, S. J. Kim, R. D. Savage, et al. Neighborhood Walkability of Retirement Homes: A Cross-Sectional Cohort Study. *J AM MED DIR ASSOC* 2019;20(1):105-06. doi: 10.1016/j.jamda.2018.09.007 pmid:304016092019-01-01].
31. Yi Zhao, Mizuki Tomita, Keitarou Hara, et al. Effects of topography on status and changes in land-cover patterns, Chongqing City, China. *LANDSC ECOL ENG* 2014;10(1):125-35. doi: 10.1007/s11355-011-0155-22014-01-01].
32. J. Lv, L. Qi, C. Yu, et al. Consumption of spicy foods and total and cause specific mortality: population based cohort study. *BMJ* 2015;351:h3942. doi: 10.1136/bmj.h3942 pmid:26242395.[(c) Lv et al 2015.:*2015-08-04].
33. WalkScore. Walk Score Methodology. In, 2020.
34. Ying Long. The Large-Scale Calculation of “WalkScore” of Main Cities in China. *New Architecture* 2018(3):4-08.
35. Tencent. Wechat official website. In, 2020.
36. Wei Tian, Jitian Song, Zhanyong Li, Pieter de Wilde. Bootstrap techniques for sensitivity analysis and model selection in building thermal performance analysis. *APPL ENERG* 2014;135:320-28. doi: <https://doi.org/10.1016/j.apenergy.2014.08.110>2014-01-01].
37. H. Kim, Y. Choi, J. Ma, et al. The Neighborhood Environment Walkability Scale for the Republic of Korea: Reliability and Relationship with Walking. *IRAN J PUBLIC HEALTH* 2016;45(11):1427-35. pmid:280320602016-11-01].
38. D. Adlakha, J. A. Hipp, R. C. Brownson. Adaptation and Evaluation of the Neighborhood Environment Walkability Scale in India (NEWS-India). *Int J Environ Res Public Health* 2016;13(4):401. doi: 10.3390/ijerph13040401 pmid:270493942016-04-02].
39. L. C. Messer, J. S. Jagai, K. M. Rappazzo, D. T. Lobdell. Construction of an environmental

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

580 quality index for public health research. *Environ Health* 2014;13(1):39. doi:
581 10.1186/1476-069X-13-39 pmid:248864262014-05-22].
582

For peer review only





Figure 1. Flow chart


506x378mm (72 x 72 DPI)




<https://openstreetmap.org/copyright> <https://openstreetmap.org>

Copyright OpenStreetMap and contributors, under an open license. For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

<https://www.openstreetmap.org/#map=12/29.5442/106.6615&layers=C>





Supplementary Table 1. The timeline of study conduction

Approval of ethic committee	2018 July 10 th
Completion of clinical registration on Chinese Clinical Trial Registry Platform	2018 August 9 th
Date collection of demographic data and home/workplace addresses of participants	2019 October
Development of Wechat mini App for recording daily steps	2020 January
Previous data checking and data collection of questionnaire and health examination of participants	2020 March-May
Date collection of daily steps of participants by Wechat mini App	2020 June
Follow-up: Data collection of questionnaire, health examination of participants, and daily steps in one month	2020 December – 2021 February
Follow-up: Data collection of questionnaire, health examination of participants, and daily steps in one month	2021 December – 2022 February
Follow-up: Data collection of questionnaire, health examination of participants, and daily steps in one month	2022 December – 2023 February

Questionnaire

Part One: Basic Personal Information

1. Name: _____
2. Physical Examination Number: _____
3. Birthplace: City_____, Province_____
4. Present Address: Number_____, Neighborhood Committee/Village_____,
Township/Street_____, District/County_____, City_____
Province_____
5. Work Address: Number_____, Neighborhood Committee/Village_____,
Township/Street_____, District/County_____, City_____
Province_____
6. Except for home and office, is there any other place you are frequently present?
- ☐Yes ☐No If yes, how long will you spend in this place in one week? ____hours
7. ID Number: _____
8. Nationality: ☐The Han Nationality ☐National Minority: _____
9. Blood Type: _____
10. Height: _____ cm
11. Weight: _____ kg
12. Education Level:
- ☐Did not attend school normally ☐Primary school or below
- ☐Junior high school ☐High school and secondary technical school
- ☐Junior college ☐Undergraduate college
- ☐Master degree and above

13. Category of Employment:

- ☐ Company employee ☐ House ☐ Student
- ☐ Active duty soldier ☐ Freelancer ☐ Industrial worker
- ☐ Self-employed people ☐ Full-time driver
- ☐ Service and sales personnel ☐ Professional and technical personnel
- ☐ Civil servant, personnel of public institutions and state-owned enterprises
- ☐ Farmers, herdsmen and fishermen ☐ Others

14. Are you currently customer of Wechat daily step calculator?

- ☐ Yes ☐ No

15. In the past week, what is your average step recorded by Wechat daily step calculator, or other step recorder? _____steps

Part Two: Family History and Personal Health Status

1. Family History (Choose the diseases which your relatives are / were diagnosed with at present / in the past from those listed below)

Are / were your parents, brothers or sisters currently diagnosed with the following diseases?
(multiple choice, put a √ under the options)

Diseases	Father	Mother	Brother	Sister
Lung cancer				
Liver cancer				
Gastric cancer				
Esophageal cancer				
Colorectal cancer				
Thyroid cancer				
Prostate cancer				
Cervical cancer				
Endometrial cancer				
Ovarian cancer				
Breast cancer				
Diabetes mellitus				
Hypertension				
Obesity				
Gout (hyperuricemia)				
Hyperlipidemia				
Asthma				
Chronic obstructive pulmonary (chronic bronchitis, emphysema)				
Stroke				
Coronary heart disease or myocardial infarction				
Osteoporosis				
Mental disease				
Other diseases				
None				

2. Personal History of Diseases

Whether the following diseases are / were diagnosed? (multiple choice)

- ☐ Lung cancer ☐ Liver cancer ☐ Gastric cancer ☐ Esophageal cancer
☐ Colorectal cancer ☐ Thyroid cancer ☐ Prostate cancer ☐ Cervical cancer
☐ Endometrial cancer ☐ Ovarian cancer ☐ Breast cancer ☐ Diabetes
☐ Hypertension ☐ Hyperlipidemia ☐ Stroke ☐ Asthma
☐ Osteoporosis ☐ Fracture ☐ Mental disorders ☐ Neurasthenia
☐ Gout (hyperuricemia) ☐ Thyroid disease (thyroiditis, nodule)
☐ Chronic cholecystitis and cholelithiasis ☐ Gastritis or duodenal ulcer
☐ Coronary heart disease or myocardial infarction
☐ Prostatic disease (hyperplasia of prostate, hypertrophy)
☐ Chronic obstructive pulmonary disease (chronic bronchitis, emphysema)
☐ Chronic liver disease (☐ hepatitis B, ☐ hepatitis C, ☐ fatty liver, ☐ alcoholic liver, ☐ liver cirrhosis)
☐ Chronic glomerulonephritis (nephritis, nephrotic syndrome, chronic renal insufficiency)
☐ Chronic breast diseases (hyperplasia of mammary glands, nodules, adenosis, cysts, etc.)
☐ Chronic gynecologic diseases (uterine fibroids, ovarian cysts, inflammations, etc.)
☐ History of operation: (The operation name:____)
☐ Other diseases ☐ None of the above diseases

3. Medication History

Do you take the following medicines for a long term? (continuous use for above 6 months, and more than once per day on average)

- ☐ Hypotensive drugs ☐ Beta blockers
☐ Psychotropic drugs ☐ Antiarrhythmic drugs

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- | | |
|---|--|
| <input type="checkbox"/> Uric acid-lowering drugs | <input type="checkbox"/> Hypoglycemic drugs |
| <input type="checkbox"/> Sedative or hypnotic drugs | <input type="checkbox"/> Hormone drugs |
| <input type="checkbox"/> Chinese herbal medicines | <input type="checkbox"/> Antipyretic analgesics |
| <input type="checkbox"/> Antiplatelet drugs such as aspirin | <input type="checkbox"/> Lipid-modulating drugs (lipid-lowering drugs) |
| <input type="checkbox"/> Angiotensin-converting enzyme inhibitors | <input type="checkbox"/> Anti-asthmatic drugs |
| <input type="checkbox"/> Others | <input type="checkbox"/> None |

For peer review only

Part Three: Eating Habits and Lifestyle

1. Eating Habit

1.1. Generally speaking, how many days during a week will you eat the following food on average? (single choice)

Rice	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Noodles	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Coarse Cereals	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Meat (pigs, cattle, sheep, poultry)	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Fish or other aquatic products	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Fresh vegetable and fruit	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Milk and dairy products	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Eggs and their products	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Beans and bean products	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Dessert (pastries, candy, etc)	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Fried food	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Pickled, smoked food	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat

1.2. In the past year, did you take the following nutrients for at least one month?

(except for ginseng)

☐ Cod liver oil / fish oil

☐ Ginseng (at least five times a year)

☐ Vitamin

☐ Other health supplements

☐ Calcium / iron / zinc

1.3. Have you ever experienced severe food shortages in your life?

☐ Yes ☐ No If not, please turn to question 4

1.3.1. In which year did you experience the most severe food shortage? _____

1.3.2. When you were experiencing the most severe food shortage:

1.3.2.1. Did your weight decrease significantly?

☐Yes ☐ No If yes, it dropped by ____ kilograms

1.3.2.2. Did you suffer from edema, severe anemia and other diseases caused by food shortages such as? ☐Yes ☐ No

1.4. In the past month, how often did you eat spicy food?

☐Never / almost never ☐1-2 days a week
☐A few times, but less than once a week on average
☐3-5 days a week ☐Every day or almost every day

1.5. How old did you begin to eat spicy food every week? ____ years old

1.6. Do you like slightly spicy food or very spicy food?

☐Slightly spicy ☐Spicy ☐Very spicy

1.7. Do you order food online?

☐Yes ☐No

1.8. How often will you order food online in one week? ____Times

1.9. What are the categories of online-ordered food you select?

☐Noodles with soup ☐Rice ☐Fried noodles ☐Dumplings
☐Sweet food, eg.cake ☐Drinks ☐Others

1.10. How often will you eat outside home (not including online order food)?
____Times

2. Smoking

Do you smoke? <input type="checkbox"/> Yes. Please answer questions 2.1, 2.2,2.5 and 2.6 <input type="checkbox"/> No. Please answer questions 2.7-2.8. <input type="checkbox"/> Quit smoking. (have quit smoking for more than one month) Please answer questions 2.3-2.6.	2.1. You began to smoke at the age of ____.
	2.2. You smoke ____ cigarettes per day on average.
	2.3. You quitted smoking at the age of ____.
	2.4. Before quitting smoking, you smoked ____ cigarettes per day on average.
	2.5. Which type of cigarettes do you smoke at present/or did you smoke before quitting? <input type="checkbox"/> Filter cigarette <input type="checkbox"/> Non-filter Cigarettes <input type="checkbox"/> Cigar <input type="checkbox"/> Hand-rolled cigarette / tobacco <input type="checkbox"/> Tobacco pipe / waterpipe smoking
	2.6. Which organ do you suck the smoke into?

	<input type="checkbox"/> To the mouth and exhale it <input type="checkbox"/> To the pharynx and larynx <input type="checkbox"/> Deep to the lung-Have you kept the habit of sucking smoke into the lung ever since you began smoking? <input type="checkbox"/> Yes <input type="checkbox"/> No
	2.7. Have you ever been exposed to the second hand smoke? <input type="checkbox"/> Yes <input type="checkbox"/> No
	2.8. How many times have you been exposed to the second hand smoke? <input type="checkbox"/> Nearly everyday <input type="checkbox"/> 4-5 days a week <input type="checkbox"/> 1-3 days a week <input type="checkbox"/> ≤1 day per week

3. Alcohol drinking

3.1. Do you drink alcohol? (Make the choice and fill in the blanks based on reality)

☐Never ☐In the past (have quit drinking for more than 6 months)

☐Yes (If yes, please answer questions 3.1.1-3.1.4)

3.1.1 You began to drink alcohol at the age of ____.

3.1.2 How often do you drink? (Single choice)

☐Twice almost everyday ☐Once almost everyday ☐3-4 times a week

☐1-2 times a week ☐Drink every month, but less than ☐Seldom
once a week

3.1.3 How much do you drink each time (only fill in the blanks with the alcohol you drink commonly)?

☐Beer, ____bottles/day

☐Yellow wine / rice wine / fruit wine, ____grams/day

☐Wine, ____grams/day

☐Liquor with a high alcohol level ($\geq 40^\circ$), ____grams/day

☐Liquor with a low alcohol level ($\leq 40^\circ$), ____grams/day

4. Sleeping (Make the choice and fill in the blanks based on reality)

4.1. How is the quality of your sleep in the past month?

☐Very good ☐Good ☐Bad ☐Very bad

4.2. How long did you sleep per day on average in the past month? ____ hours

4.3. Did you need to take medicine to help you fall asleep in the past month?
(medicine prescribed by the doctor or purchased by yourself)

- ☐No ☐ < Once every week on average
☐ Once-twice every week on average ☐ ≥ 3 times every week on average

5. Physical activity

5.1. In the past year, what is your activity status during work?

- ☐ Sedentary ☐ Standing ☐ Activity with medium amount
☐ Activity with heavy work load ☐ Retired or disabled to work

5.2. What is your average working hour in one week? _____ hours

5.3. In the past your, what is your transportation way to go to work?

- ☐ Walking ☐ Driving ☐ Taking a bus
☐ Riding a bike ☐ Work at home ☐ Others
or the place closed to home

5.4. How long is the commuting time of your work? _____ min

5.5. In the past one year, what is your physical activity frequency?

- ☐ Never ☐ 1-3 times one month ☐ 1-2 times one week
☐ 3 -5 times one week ☐ Almost everyday

5.6. What is the exercise way you did the most frequently?

- ☐ Taichi/Walking ☐ Fast walking ☐ Running/or other aerobics
☐ Swimming ☐ Ball game ☐ Others(such as hiking)

5.7. During the last 7 days, on how many days did you do vigorous physical activities
like heavy lifting, digging, heavy construction, or climbing up stairs as part of your
work?

_____ days per week

5.8. How much time did you usually spend on one of those days doing vigorous
physical activities as part of your work?

_____ hours per day, _____ minutes per day

5.9. During the last 7 days, on how many days did you do moderate physical activities like carrying light loads as part of your work? Please do not include walking.

_____ days per week

5.10. How much time did you usually spend on one of those days doing moderate physical activities as part of your work?

_____ hours per day, _____ minutes per day

5.11. During the last 7 days, on how many days did you walk for at least 10 minutes at a time as part of your work?

_____ days per week

5.12. How much time did you usually spend on one of those days walking as part of your work?

_____ hours per day, _____ minutes per day

5.13. During the last 7 days, how much time did you usually spend sitting on a weekday?

_____ hours per day, _____ minutes per day

5.14. Did you use sport watch or app for record steps or heart rate?

☐ Yes ☐ No

If yes, the name of sport watch is _____, the name of the sport app is _____

6. Others

6.1. Are you satisfied with your current living conditions?

☐ Cannot be more satisfied ☐ Basically satisfied

☐ Ordinary ☐ Dissatisfied ☐ Very dissatisfied

6.2. Did you experience the events that have a significant impact on your life in the past two years, such as those listed below?

☐ Marital separation/divorce ☐ Serious trauma or car accident

☐ Unemployment / laid-off / retirement ☐ Death of spouse

☐ Serious family diversity and conflicts ☐ Violent attacks / rapes

☐ Loss of economic resources / liabilities

☐ Bankruptcy of self-owned business or family economic breakdown

☐ Death or serious diseases of other family members

☐ Serious natural disasters (such as drought, waterlogging, etc.)

☐ None

6.3. In the past year, are you under great mental stress in work and life?

- ☐No pressure ☐Little pressure ☐Ordinary
☐Great pressure ☐Extremely great pressure

6.4. In the past one year, is any change in your body weight?

- ☐No ☐Add at least 2.5kg ☐Lose at least 2.5kg

6.5. In the past one year, do you using drugs or controlling diet intake in order to lose weight?

- ☐Yes ☐No

6.6. Could you remember your body weight when you was at age of 25?

_____kg; ☐Not applicable

Signature_____

Variable category	Name of variable	Normal limits or categories	Definition of variables	Data resources
Primary outcomes	body mass index	18.5-24kg/m2	outcome	calculate from health examination information
	daily steps in one month		mediator and outcome	Wechat mini application
Secondary outcomes	fasting blood glucose (GLU)	3.6-6.1 (mmol/L)	outcome	health examination
	total cholesterol (TC)	3.1-5.7 (mmol/L)	outcome	health examination
	triglyceride (Tg)	0.4-1.73 (mmol/L)	outcome	health examination
	low density lipoprotein cholesterin (LDL-C)	2.07-3.1 (mmol/L)	outcome	health examination
	high density lipoprotein cholesterin (HDL-C)	0.9-2 (mmol/L)	outcome	health examination
	body composition	mass percentage of fat	outcome	health examination
Exposure variables	WalkScore corresponding to home address	0-100	exposure	calculate from questionnaire information
	WalkScore corresponding to workplace address	0-100	exposure	calculate from questionnaire information
Other variables	height			health examination
	weight			health examination
	age	16 - 65 years old	possible confounding	questionnaire
	gender	male; female	possible confounding	questionnaire
	job		possible confounding	questionnaire
	education	under primary school; primary school, middle school; bachelor; master and a	possible confounding	questionnaire
	smoking status	giving up; never; sometimes smoke; frequently smoke	other factors will influence outcome	questionnaire
	alcohol consumption	giving up; never; sometimes drink; frequently drink	other factors will influence outcome	questionnaire
	online food order habit	never; sometimes order; frequently order	possible confounding	questionnaire
	eating diet	more details showed in questionnnaire	other factors will influence outcome	questionnaire
	physical activity	more details showed in questionnnaire	possible confounding	questionnaire

The name of health examination	Specific name of items	Normal limits or result categories
Five items of thyroid function	Free triiodothyronine (FT3)	2.0-6.6 pmol/L
	Free thyroxine (FT4)	10.3-31.0 pmol/L(0.8~2.3ng/dL)
	Thyroid-stimulating hormone (TSH)	0.3-4.5 uIU/mL
	Total triiodothyronine (TT3)	1.8-2.9 nmol/L(115~190ng/dL)
	Total thyroxine (TT4)	65-155 nmol/L(5.0~12.0µg/dL)
12-leads electrocardiogram		N=Normal; A=abnormal
Ultrasound (splenorenal major abdominal and portal vein)		
	Liver	N=Normal; A=abnormal
	Gallbladder	N=Normal; A=abnormal
	Pancreas	N=Normal; A=abnormal
	Spleen	N=Normal; A=abnormal
	Bilateral kidneys	N=Normal; A=abnormal
	Portal vein	N=Normal; A=abnormal
Carcinoembryonic antigen (CEA)		0-5 (ng/ml)
Liver function	Albumin (Alb)	38-51 (g/L)
	Albumin/Globulin	1.2-2.5
	Gamma-glutamyl transpeptidase (GGT)	4-50 (IU/L)
	Alanine amino transferase (ALT)	0-42 (IU/L)
	Aspartate amino transferase (AST)	0-42 (IU/L)
	Alkaline Phosphatase (ALP)	34-114 (IU/L)
	Globulin (G)	25-38 (g/L)
	Total protein (TP)	66-83 (g/L)
Alpha-fetoprotein (AFP)		0-20 (ng/ml)
Urine routine	Potential of hydrogen (PH)	4.6-8.0
	Urine leukocyte (LEU)	Negative or positive
	Specific gravity (SG)	1.003-1.03
	Bilirubin (BIL)	Negative or positive
	Urobilinogen (URO)	N=Normal; A=abnormal
	Urine protein (PRO)	Negative or positive
	Urine Casts	Negative or positive
	Urine erythrocyte (ERY)	Negative or positive
	Urine pus cells	Negative or positive
	Urine colour	Negative or positive
	Uroepithelial cell (U-Epc)	Negative or positive
	Urine sugar (U-GLU)	Negative or positive
	Urine ketone (KET)	Negative or positive
	Urine nitrite (NIT)	Negative or positive
	Urine transparency	Negative or positive

	Urinary mucous silk (U-MUCS)	Negative or positive
	Creatinine (CR)	45-84 (μmol/L)
	Blood urea nitrogen (UN)	1.7-8.3 (mmol/L)
	Uric acid (UN)	155-428 (μmol/L)
	Fasting blood glucose (GLU)	3.6-6.1 (mmol/L)
	Serum cystatin c (Cys-c)	0.5-1.1 (mg/L)
Blood routine		
	white blood cell (WBC)	3.5-9.5 (10 ⁹ /L)
	Percent monocytes (MON%)	3-10 (%)
	Monocytes (MON)	0.1-0.6 (10 ⁹ /L)
	Red blood cell (RBC)	3.8-5.1 (10 ¹² /L)
	Red blood cell distribution width (SD)	11-16 (%)
	Red blood cell distribution width (CV)	37-54 (fL)
	Hematokrit (HCT)	35-45 (%)
	Percent lymphocyte (LYMPH%)	20-50 (%)
	Lymphocyte count (LYMPH)	1.1-3.2 (10 ⁹ /L)
	Mean corpuscular volume (MCV)	82-100 (fL)
	The average RBC hemoglobin content (MCH)	27-34 (pg)
	The average RBC hemoglobin concentration (MCH)	316-354 (g/L)
	mean platelet volume (MPV)	9-13 (fL)
	Basophilic cell percentage (BAS%)	0-1 (%)
	absolute basophil count (BAS)	0-0.06 (10 ⁹ /L)
	Acidophilic cell percentage (EOS%)	0.4-8 (%)
	Acidophil number (EOS)	0.02-0.52 (10 ⁹ /L)
	Hemoglobin (HGB)	115-150
	Platelet distribution width (PDW)	9-17 (%)
	blood platelet count (PLT)	125-350 (10 ⁹ /L)
	Thrombocytocrit (PCT)	N (%)
	Neutrophilic granulocyte percentage (NEU%)	40-75 (%)
	Neutrophilic granulocyte count (NEU)	1.8-6.3 (10 ⁹ /L)
Blood lipid		
	Total cholesterol (TC)	3.1-5.7 (mmol/L)
	Triglyceride (Tg)	0.4-1.73 (mmol/L)
	Low density lipoprotein cholesterin (LDL-C)	2.07-3.1 (mmol/L)
	High density lipoprotein cholesterin (HDL-C)	0.9-2 (mmol/L)
Two pairs of semi - hepatitis B		
	Hepatitis B e antibody (HBe)	Negative or positive
	Hepatitis B e antigen (HBeAg)	Negative or positive

	Hepatitis B surface antibody (HBs)	Negative or positive
	Hepatitis B surface antigen (HBsAg)	Negative or positive
	Hepatitis B core antibody (HBc)	Negative or positive
Ultrasound(bilateral mammary gland)		N=Normal; A=abnormal
Ultrasound(uterus, annex)		N=Normal; A=abnormal
Vaginal secretion examination	Trichomonad	Negative or positive
	Mycete	Negative or positive
	Cleanliness of leucorrhea	Negative or positive
Thinprep cytology test(TCT)		N=Normal; A=abnormal
Body composition		Mass percentage of fat, protein, and water

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract P2 (b) Provide in the abstract an informative and balanced summary of what was done and what was found P2
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported P3
Objectives	3	State specific objectives, including any prespecified hypotheses P3
Methods		
Study design	4	Present key elements of study design early in the paper P5-P6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection P4-P7
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up P4-P5 <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed P6 <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable P4-P7
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group P6-P7
Bias	9	Describe any efforts to address potential sources of bias P6-P7
Study size	10	Explain how the study size was arrived at P6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why P7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding P7 (b) Describe any methods used to examine subgroups and interactions P7 (c) Explain how missing data were addressed P7 (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed P7 <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses P6

Continued on next page

Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount) P7
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18	Summarise key results with reference to study objectives
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias P7
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence P7
Generalisability	21	Discuss the generalisability (external validity) of the study results P7
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

The effects of walkability on physical activity and obesity: a prospective observational study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034882.R3
Article Type:	Protocol
Date Submitted by the Author:	20-Aug-2020
Complete List of Authors:	Zhang, Yalan; Army Medical University, Health Management Centre Chen, Siyu; Army Medical University, Department of Epidemiology and Biostatistics Shi, Jiayang; Army Medical University, Health Management Centre Chen, Zongtao; Army Medical University, Health Management Centre
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Epidemiology, Public health, Sports and exercise medicine
Keywords:	EPIDEMIOLOGY, SPORTS MEDICINE, CLINICAL PHYSIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

The effects of walkability on physical activity and obesity: a prospective observational study protocol

Yalan Zhang^{1¶}, Siyu Chen^{2¶}, Jiayang Shi¹, Zongtao Chen^{1*}

¹Health Management Centre, First Affiliated Hospital (Southwest Hospital), Army Medical University, Chongqing, P.R. China.

²Department of Epidemiology and Biostatistics, First Affiliated Hospital (Southwest Hospital), Army Medical University, Chongqing, P.R. China

*Corresponding author

E-mail: chenzongtao@126.com

¶These authors contributed equally to this work.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

29 **Abstract**

30 Introduction

31 The prevalence of overweight and obesity is increasing worldwide, which could lead to a set of
32 chronic and metabolic diseases. Physical activity is a modifiable factor for obesity, which was
33 reported to be correlated with built environment. However, the effects of built environment on
34 physical activity are not consistent. Walkability is a convenient way to assess built environment.
35 We aim to prospectively explore the relationship among walkability, physical activity, and obesity
36 in Chinese participants in Chongqing, a hilly city, and provide evidence for future urban planning.

37
38 Methods and analysis

39 Participants will be recruited from people who receive health examination in the Health
40 Management Centre, the First Affiliated Hospital to Army Medical University. Exposure variables
41 are WalkScores calculated within the areas around workplace and residential addresses of
42 participants. The primary outcomes are body mass index (BMI) measured through health
43 examination at baseline and follow-ups, and daily walking steps recoded by WeChat mini
44 application for 30 days after every time of health examination. Other health-related data of the
45 participants will also be collected. Multivariate regression analysis will be performed to examine
46 the relationship between exposure variables and outcomes.

47
48 Ethics and dissemination

49 The Protocol is approved by the Ethics Committee of the First Affiliated Hospital to Army Medical
50 University (KY201839). The results will be actively disseminated through peer-review journals
51 and conference publications.

52
53 **Strengths and limitations of this study**

- 54 -This study innovatively evaluates the effects of walkability on physical activity and obesity in a
- 55 hilly city prospectively.
- 56 - The daily walking steps were recorded using a novel method, WeChat mini application.
- 57 -This study combines the data collected from health examination and cellphones.
- 58 -One limitation is that WeChat mini application would fail to record daily walking steps during
- 59 swimming and other physical activities without cellphones.
- 60 -The other limitation is the maximum time for data collection is 30 days after one authorization.

Introduction

The prevalence of overweight and obesity has doubled worldwide since 1980, which is currently 5% in children and 12% in adults.¹ In 2015, the number of children and adults who suffered from obesity was 107.7 million and 603.7 million, respectively.² High body mass index (BMI), an indicator for obesity, was identified to be a risk factor for various chronic diseases, including cardiovascular disease, diabetes, chronic kidney disease, and cancers.² Chinese Health and Nutrition Survey showed the rate of obesity and overweight in adults increased from 25.1% to 39.6% from 1997 to 2009.³ The updated prevalence of overweight and obesity were reported to be 25.8% and 7.9%, respectively, in 2017.⁴ It is reported that the obesity rate in Chongqing in Southwestern China is 10.3%.⁵⁻⁶

One of the modifiable risk factors of obesity and chronic diseases is physical inactivity.⁷⁻⁸ Physical activity indicators are correlated with some metabolic indicators.⁹ Physical inactivity is partly due to insufficient activity during leisure time and an increase in sedentary behavior during occupational and domestic activities.¹⁰ Additionally, an increase in the use of "passive" modes of transport such as taking a car or a bus has also been associated with declining physical activity levels, which means less walking or any human powered movement in daily life.¹⁰ Insufficient physical activity contributes to 6% of the disease burden of coronary heart disease, 7% of that of type 2 diabetes, 10% of that of breast cancer, and 10% of that of colon cancer.¹¹ As reported, more than 533,000 deaths and more than 1.3 million deaths could be averted annually by reducing the prevalence of physical inactivity by 10% and 25%, respectively.¹¹ Thus, in order to ameliorate physical inactivity, it is crucial to understand its associated factors and determinants. The factors associated with physical activity in high-income countries were reported to be age, sex, health status, self-efficacy, genetic factors, and motivation.¹² At the level of population, the factors outside health sectors have been identified to be causally related to physical inactivity, for example, urban planning, transportation system, and built environment.¹²⁻¹⁴

Walkability is a useful tool in the process of evaluating the effects of the built environment on physical activity.¹⁵ However, the evidence on the associations among the built environment, walkability, physical activity, and health is inconsistent. A study published in *Nature* in 2017 with more than 700 thousand participants and 68 million days recorded revealed that higher walkability was associated with more daily walking steps, whose effect was stronger for females.¹⁵ Porter and colleagues also indicated in a cohort study with 688 participants that as one aspect of the neighborhood environment, walkability was associated with physical activity among pregnant women.¹⁶ Other studies from Japan and North America also supported the positive effects of built environment on physical activity.¹⁷⁻¹⁹ In a middle size city Bengbu in Eastern China, researchers observed about at least 30% lower risk of cardiovascular diseases were associated with moderate to high levels of WalkScore, compared with controls with low WalkScore, in which WalkScore is a measure of walkability.²⁰ However, a cohort study with 1819 households investigating moving to the former Olympic athletes' village in London discovered no effect associated with this living environment change on daily walking steps, indicating that ameliorating the built environment might be insufficient to enhance physical activity.²¹ A study with 161 older adult participants in Canada also showed that walkability was not associated

with physical activity volume or intensity.²² A study in a small city in China called Yuncheng also showed no positive associations of land-use mix and walking duration.²³ In addition to these inconsistent evidence, there is no research of walkability effects on physical activity and health in China.

The factors of walkability usually include residential housing units, retail shops, public transportation, street-level movement density, the distance to behavior-related destinations.²⁴⁻²⁹ Residential housing units are a house, apartment, group of rooms, or a single room for occupancy as a separate living unit, which could predict the population allocation in an area.³⁰ Retail shops are one kind of points of interest, which serve for non-residential uses and can enhance the motivation of walking.²⁵ Accessibility, which are represented by the street-level movement density and the distance to behavior-related destinations, as well as the proximate access to public transportation are crucial characteristics of a walkable neighborhood.²⁶ Some studies also take into account the population density, the street connectivity, land-use diversity, infrastructure and safety for walking, aesthetics, and crime influence.²⁷⁻²⁹ WalkScore (www.WalkScore.com) is a user-friendly open composite walkability index. It could evaluate the walkability of a mail address or a city and is widely used in the studies investigating the relationship between walkability and health status.^{15,31}

The evaluation of the walkability of a community and its effects on physical activity and health status of the residents in China could shed a light on urban design, laying a foundation for future urban planning policy and physical activity promotion interventions. Additionally, there is a gap of research on the influences of walkability on the physical activity in a hilly city. This protocol is an observational, prospective cohort study of participants who receive health examination in the First Affiliated Hospital to Army Medical University. The aim of this study is to analyze the relationships among walkability, physical activity, and obesity in the residents in Chongqing for future urban planning reference. Previous literature shows lower hilliness is associated with enhanced physical health.³² Our research hypothesis is that high WalkScore will be associated with the decrease of BMI under the context of a hilly city. The daily walking steps and metabolic profiles will be the mediators through the effect pathway from WalkScore to BMI.

We illustrate our hypothesis of causal diagram in Supplementary Figure 1. Obesity and overweight are the primary outcomes. WalkScore is the exposure variable. Daily walking steps and metabolic profiles are the mediator from WalkScore to obesity.^{9,33-34} Job and education are possible confoundings between WalkScore and daily walking steps.³⁵ Physical activity is possible confounding between daily walking steps and metabolic profiles.^{9,36} Online food order habit is possible confounding between WalkScore and metabolic profiles. Eating habit, smoking, and alcohol consumption are other factors, which will influence metabolic profiles.³⁷⁻³⁹

Materials and Methods

Study design and setting

Our protocol is an observational, prospective cohort study. The location of our protocol is Chongqing, a Chinese city, with multi-commercial centres, which is characterized by a unique hilly topology with two rivers, Yangtze and Jialing.⁴⁰ A map and photos with the hilly topography of Chongqing are showed in Supplementary Figure 2. Blood samples, clinical data, addresses, and related variables are collected prospectively from participants who receive health examination in the Health Management Centre, First Affiliated Hospital to Army Medical University, Chongqing. Clinical and demographic data are recorded in the hospital's database. The daily walking steps of participants are collected by WeChat mini application. Blood samples are examined by the clinical laboratory of the hospital. The home and workplace addresses and the part of listed variables in Table 1 will be collected by a questionnaire referred to a comprehensive cohort study named China Kadoorie Biobank study.⁴¹ Participants will be recruited from October 2019 to 2020 and followed up till 2023. The recruitment period will be extended if necessary. The recruitment process can be referred to Figure 1 and the timeline is showed in Supplementary Table 1. Moreover, we will include the participants who decided an examination appointment before health examination day if he/she meets the inclusion/exclusion criteria. We need to require this kind of participants to provide home and workplace addresses on the first visit and fill questionnaire on the health examination day.

In the baseline, the specific recruitment and data collection procedure are as follows. Stage 1: after participants signed informed consent, we collected demographic data and home/workplace addresses information in 2019 October. The recruitment time will be extended to 2020 May. Stage 2: Before or on the health examination day in 2020 March-May, we will check the inclusion/exclusion criteria and screened the participants for the first time. Stage 3: collecting questionnaire on the health examination day in 2020 March-May. Stage 4: requesting participants to install WeChat mini application and endow authorization on the health examination day in 2020 March-May. Stage 4: health examination including blood sample collection and height/weight measurement are conducted. Stage 5: daily steps in 30 days will be collected after the day of health examination. Stage 6: the inclusion/exclusion criteria will be checked secondly after data collection.

In the three times follow-ups in 2021, 2022, and 2023, the data collection procedure is similar to those in the baseline. Stage 1: collecting demographic data and updating home/workplace addresses information. Stage 2: collecting questionnaire. Stage 3: requesting participants to install WeChat mini application and endow authorization. Stage 4: health examination including blood sample collection and height/weight measurement are conducted. Stage 5: daily steps in 30 days will be collected after the day of health examination.

190 Table 1. All measured variables.

Variable category	Name of variable	Normal limits* or categories	Definition of variables**	Sources of data
Primary outcomes	Body mass index	18.5-24kg/m2	Outcome	Calculate from health examination data (height and weight)
	Daily walking steps in one month		Outcome and mediator	WeChat mini application
Secondary outcomes	Fasting blood glucose (GLU)	3.6-6.1 (mmol/L)	Outcome	Health examination
	Total cholesterol (TC)	3.1-5.7 (mmol/L)	Outcome	Health examination
	Triglyceride (Tg)	0.4-1.73 (mmol/L)	Outcome	Health examination
	Low density lipoprotein cholesterin (LDL-C)	2.07-3.1 (mmol/L)	Outcome	Health examination
	High density lipoprotein cholesterin (HDL-C)	0.9-2 (mmol/L)	Outcome	Health examination
	Body composition	Mass percentage of fat	Outcome	Health examination
Exposure variables	WalkScore corresponding to home address	0-100	Exposure	Calculate from questionnaire information
	WalkScore corresponding to workplace address	0-100	Exposure	Calculate from questionnaire information
Other variables	Height			Health examination
	Weight			Health examination
	Age	16 - 65 years old	Possible confounding	Questionnaire
	Gender	Male; female	Possible confounding	Questionnaire
	Job		Possible confounding	Questionnaire
	Education	Under primary school;	Possible confounding	Questionnaire

		primary school, middle school; bachelor; master and above		
	Smoking status	Giving up; sometimes frequently smoke	never; smoke; outcome	Other factors will influence outcome
	Alcohol consumption	Giving up; sometimes frequently drink	never; drink; outcome	Other factors will influence outcome
	Online food order habit	Never; sometimes frequently order	order; outcome	Possible confounding
	Eating diet	Not applicable		Other factors will influence outcome
	Physical activity	Not applicable		Possible confounding

*"Normal limits" means in these limits, the corresponding condition is normal, otherwise it suggests there may be some health concerns or some errors.

**The definition of variables can be referred to Supplementary Figure 1.

Participants

This is an open cohort study. Participants are eligible for inclusion if they satisfy the following criteria: an age between 16 and 65, using smart phones, habitual residents in the downtown area of Chongqing.

The exclusion criteria will be: 1. participants with the symptoms or signs of cardiovascular and cerebrovascular diseases, such as chest tightness, shortness of breath, and even chest pain, especially those whose symptoms get worse when climbing stairs or walking fast; 2. participants with diagnosed heart diseases, such as coronary heart diseases, hypertensive heart diseases, valvular heart diseases, and pulmonary heart diseases, who need to exercise based on principles of cardiac rehabilitation; 3. participants with other severe complications of diabetes, such as those with vision severely affected by eye diseases, those with balancing ability affected by peripheral neuropathy, those with diabetic foot, and those with renal dysfunction; 4. participants whose movement is affected by musculoskeletal disorders, e.g. patients with musculoskeletal disorders and cardiopulmonary dysfunction; 5. participants who refuse to provide corresponding information, or are not able to complete the questionnaire and health examination (This item should also be checked in data cleaning stage); 6. participants who plan to migrate to other areas or leave for a long time (more than one year); 7. participants with secondary morbid obesity caused by congenital diseases, metabolic diseases, neurologic diseases and endocrine diseases. After checking the inclusion/exclusion criteria, the participants are planned to be recruited. Participants must be able to sign written informed consent after acknowledging the benefits and risks of this study. Participants information will be checked and the follow-ups will be traced by the health managers and nurses in the Health Management Centre.

The number of the sample size was calculated using the following formula:

$$n = \frac{\left(z_{\alpha} \sqrt{2pq} + z_{\beta} \sqrt{p_0 q_0 + p_1 q_1} \right)^2}{\left(p_1 - p_0 \right)^2}$$

The parameters used in the calculation are: p_0 (the obesity prevalence in control group) as 10.3%,⁶ the supposed risk ratio (RR) between groups with high WalkScore and low WalkScore as 0.5, $\alpha = 0.05$, and $1 - \beta = 0.9$. In this formula, $p_1 = p_0 * RR = 5.15\%$, $\bar{p} = (p_0 + p_1) / 2$, $\bar{q} = 1 - \bar{p}$, $q_0 = 1 - p_0$, and $q_1 = 1 - p_1$, $Z_{\alpha} = 1.96$, and $Z_{\beta} = 1.282$. Based on these parameters, the sample size in exposure group and control group should be 400, respectively. Concerning the possibility of loss of follow-up, we increased the sample size by 10% to 440 participants in each group. The final sample size is 880 in total.

Measures

The questionnaire (full version of the questionnaire is attached in Supplementary File 1) filled by

participants under nurses' guidance includes the questions of participant demographics, exposure, and lifestyle factors. The measured variables, primary outcome, and secondary outcomes, exposure variables, as well as possible confoundings are listed in Table 1. The variables in detail are showed in Supplementary File 2. The relationships among different variables are illustrated in a causal diagram in Supplementary Figure 1.

During the process of data collection, the following data were collected by the questionnaire and health examination procedure as well as WeChat mini application:

1. Primary outcomes: Body mass index (BMI), and everyday walking steps are recorded by a WeChat mini application. Every year, the daily walking steps in 30 days will be collected after health examination in the hospital. BMI was calculated by the weight in kilograms divided by the square of the height in meters. Overweight and obesity were defined as a BMI of 24–27.9 kg/m² and a BMI \geq 28 kg/m², respectively.⁴ The participants will authorize the application in order to allow the researchers in this study to obtain the daily walking steps in 30 days collected by the WeChat mini application (They only need to record walking steps of 30 days once a year).
2. Secondary outcomes: metabolic profiles by blood tests; for example, cholesterol levels and blood glucose. Body composition was measured by a machine named inbody 220, when doing the measurement in which, the participants will stand on the machine without shoes and hold the two poles of the machine for five minutes.
3. Exposure variables: Walkscores which will be calculated based on the workplace address and residential address of the participants.
4. Participant demographics: age, gender, height, marital status, and education.
5. Lifestyle factors: smoking status, alcohol consumption, online food order habit, eating diet, and physical activity
6. Identification of non-communicable diseases: e.g. hypertension, coronary artery disease, and diabetes.

Biological samples and assay methods

The blood samples are collected by nurses in the Health Management Centre in the morning. The participants should be fasting for 12 to 14 hours before health examination. A sum of 5mL blood was collected in the yellow tube with inert separating gel for cholesterol and glucose testing. A total of 2mL blood for blood routine test was stored in a purple tube with ethylenediaminetetraacetic acid (EDTA) as anticoagulant. The blood samples are analyzed by automated biochemical analyzer, with the series number of Beckman AU5811. Total cholesterol was tested by the cholesterol oxidase (CHO) enzyme method. Triglyceride was tested by the glycerol phosphate dehydrogenase and peroxidase (GPO-POD) method.

Physical examination

The physical examination included the measurement of height, body weight, blood pressure, and body component following the guidelines of the Health Management Centre. The blood pressure was evaluated by electronic sphygmomanometer (Omron, type: B-203RV III C). The machine Inbody 220 was used to analyze body component including the proportion of water, protein,

mineral salt, and fat.

WalkScore

WalkScore measures pedestrian friendliness by analyzing the distance to points of interest and the weights of points of interest. Data sources are from Google, Factual, Great Schools, Open Street Map, the U.S. Census, Localeze, and places added by the Walk Score user community.⁴² The algorithm of WalkScore is not disclosed in its official website. The formula⁴³ of WalkScore illustrated in Tsinghua University is

$$\sum_{i=1, j=1}^{m,n} (W_i * S_{i,j} * D_{i,j}) * \frac{100}{15}$$

W_i is the weight of one kind of amenity. Table 2 shows the weights of different amenities.

Amenity's name	Weight	Amenity's name	Weight	Amenity's name	Weight
convenience store	3	café/teahouse	2	school	1
restaurant	3	bank	1	bookstore	1
shop	2	park	1	entertainment places	1

Table 2. Weights of different amenities.

The letter of i stands for different kinds of amenities. The letter of j stands for different walking distance. $S_{i,j}$ stands for service scope of a specific amenity. $D_{i,j}$ stands for the attenuation coefficient based on distance from the calculated point to an amenity. Table 3 shows the attenuation coefficients based on the distances from the calculated point to an amenity.

Distances	Attenuation coefficients
<400 metres	1
400-800 metres	0.9
800-1200 metres	0.55
1200-1600 metres	0.25
1600-2400 metres	0.08
>2400 metres	Out of distance scope, which will not be calculated.

Table 3. Attenuation coefficients based on the distances.

The calculation of WalkScore is free, to obtain which we could type the name of calculated point into the official website/cellphone application and wait for the score (www.WalkScore.com). The limit of the score is 0-100. The WalkScore of residential address and workplace address will be calculated separately.

The following Table 4 describes the meanings of different WalkScore.

WalkScore	Description
90 - 100	Walker's Paradise: Daily errands do not require a car.
70 - 89	Very Walkable: Most errands can be accomplished on foot.
50 - 69	Somewhat Walkable: Some errands can be accomplished on foot.
25 - 49	Car-dependent: Most errands require a car.
0 - 24	Almost all errands require a car.

Table 4. Interpretations of different WalkScore.

WeChat mini application

WeChat is a cellphone application for communication used by more than a billion people.⁴⁴ The customers of it can send voice, video, photos, and text. On the basis of WeChat and its great number of users, the company of WeChat opens the resources to the public of developing different kinds of WeChat mini applications. Users could link its WeChat ID to WeChat mini application without download installment package and achieve data sharing through WeChat mini application. WeChat could also record daily step data from users' cellphones after user's agreement. Through WeChat mini application, we could extract the daily walking steps of WeChat users in one month after customer agreement. After we develop the WeChat mini application following the guideline from WeChat and publish it, the participants could open the WeChat mini application in their WeChat and signed a second consent to agree that they are willing to allow us extract daily steps on the platform of WeChat. Then, the customers' daily step information will be delivered to our datasets automatically. The obtained data will be consistently with the records in participants' cell phones.

Statistical methods

The data analysis will be conducted after data collection in 2020. The prospective analysis will be implemented in 2023. Stata (Version 14.0, Stata Corp., College Station, TX, USA) and R (Version 4.0.2) will be used for data analysis. Descriptive statistics is performed to analyze the distribution of the data. Missing data were addressed by deletion or last observation carried forward based on specific case status. Single variable analysis will be implemented to analyze the correlations between exposures, possible confoundings (i.e., online food order habit, education, job, physical activity), and outcomes. The participants will be divided into five groups by the categories of the WalkScore with regard to workplace address and residential address, respectively. The lifestyle factors and outcomes will be compared among groups. All the variables in causal diagrams will be compared between baseline and follow-ups. T-test will be used for comparing the difference of the continuous variables in two groups, and Chi-square test or Analysis of Variance (ANOVA) will be used for comparing the difference of categorical variables in different groups. Multivariate linear regression will be conducted taken BMI and daily walking steps as dependent variables, respectively, as cross-sectional analyses, after data collection in 2020. Sensitivity analysis will be

implemented by bootstrap method. With replacement from the original dataset, the bootstrap method enables estimation of the accuracy of an estimator by random sampling. Further longitudinal analyses with G estimation and inverse probability weight analysis will be conducted after data collection in 2023 in order to take into account the effects of confounders whose conditions may change over time. The first step is to determine the ranges and variations of the independent variables, which are input into our multivariate linear regression. The second step is to generate independent variables based on the Sobol sequence by R package “randtoolbox”. The final step is to collect and process the simulation results, which can be used in sensitivity analysis through conducting multivariate linear regression.⁴⁵

Patient and public involvement

Our study is an observational study without intervention on participants. The development of the research question and outcome measures were informed by participants’ priorities, experience, and preferences on the basis of informed consents. There is no participants’ involvement in the study design. We recruit participants when conducting the study, but participants would not be the conductor of the study. The results are planned to disseminate to study participants.

Ethics and dissemination

The Protocol is approved by the Ethics Committee of the First Affiliated Hospital to Army Medical University (KY201839). All the participants will receive consultation about the benefits and possible risks of the study from health managers and nurses, and endow written informed consent before enrollment. All the participants will be informed that they can withdraw from the study at any time for any reason. The withdrawal cases will be discarded and related information will be deleted from the database of the study.

The sample volume of blood for the study is 11 per participant-visit and maximum 55 for five years. The blood sampling process is part of the procedure of health examination and this study acquires the data use authority after the recruitment. The participants will be contacted and informed the results of the health examination. The researchers of this study will be responsible for implementing the study adhering to the Declaration of Helsinki.

We plan to analyze and publish study results according to the STROBE guidelines. Results will be published in international and peer-reviewed scientific journals. Negative, positive, conclusive or inconclusive results will be published.

Study Status

We collected demographic data, home addresses, and workplace addresses of participants in October 2019. We plan to check previous data and collect the data of health examination and questionnaire of participants in March to May 2020 and daily walking steps of participants by WeChat mini application in 2020 (in one month after health examination). We will continue

follow-up in 2021-2023. The follow-up will be sustained by contacting with participants and requiring health examination by phone. Currently, the daily walking steps collector of the WeChat mini application has been developed. The study was registered in Chinese Clinical Trial Registry (ChiCTR) and the registration number is ChiCTR1800017680. The date of the study in a timeline is showed in Supplementary Table 1. There will be six waves of data collection.

Discussion and potential limitations

This observational and prospective study could innovatively provide evidence of the relationship among walkability, obesity, and physical activity in China. It will also provide evidence of the influence of built environment on physical activity in a hilly city, Chongqing. We hypothesized that the walkability, physical activity, and obesity status are strongly associated with each other. The use of WeChat mini application in data collection process have a lot of advantages. Through extracting data from cellphones' records, the data collection is very convenient and cost-effective which eliminates the errors of manual typing. The participants will sign informed consents before recruitment and sign an agreement to endow WeChat mini application to collect their daily steps before the use of WeChat, in which way we could ensure the process meets the ethic requirements.

There are some limitations in the collection of physical activity. The WeChat mini application can only record the daily walking steps when the participants walk with their phone. Like other studies, activities without carrying phones such as swimming and ball games will not be recorded in the data collection procedure.¹⁵ Moreover, more than 30 days' collection needs second authorization (the maximum data collection time is 30 days after one authorization) which is less adherent; thus the researchers could only collect the data of 30 days in one year for convenience. In order to compensate for this limitation, the participants will be recruited all year round and the researchers will ask for a second authorization of daily step collection in the follow-up visit. In terms of season, the season when we do the data collection may also influence the number of daily steps. We will consider season as a confounder in future data analysis.

Moreover, WalkScore is based on an online calculation website which has not opened the algorithm officially. Other walkability evaluation tools such as Pedestrian Environment Quality Index (PEQI) depend on the evaluation of geographic information system (GIS), the score process of which is relatively clean; however, the practice is more complex.⁴⁶⁻⁴⁸ Thus, we decide to choose WalkScore for the exploratory study. If the results could indicate a strong relationship between walkability and obesity, we could further analyze the specific component factors such as the diversity of points of interests of walkability in following analysis.

Legends

Supplementary Figure 1. Causal diagram of measured variables.

Obesity and overweight are the primary outcomes. WalkScore is the exposure variable. The participants will be divided into five groups by the categories of the WalkScore with regard to workplace address and residential address, respectively (In this way, we decide the exposure

degree). Daily walking steps and metabolic profiles are the mediator from WalkScore to obesity. Job and education are possible confoundings between WalkScore and daily walking steps. Physical activity is possible confounding between daily walking steps and metabolic profiles. Online food order habit is possible confounding between WalkScore and metabolic profiles. Eating habit, smoking, and alcohol consumption are other factors, which will influence metabolic profiles.

Supplementary Figure 2A. Chongqing map.

It is the nine main districts of Chongqing extracted from Open Street Map. The black point shows the location of the First Affiliated Hospital to Army Medical University in Shapingba District. Shapingba District is an old town with a lot of renowned high schools and universities.

Supplementary Figure 2B. Chongqing location.

It shows the location of Chongqing relative to the other cities (Chengdu, Suining, Zigong, Jianyang, and so on). The topography of Chongqing is more hilly than that of Chengdu.

Figure 1. Flow chart of study.

Supplementary Table 1. Timeline of study conduction.

Funding: there is no funding.

Acknowledgements: Thanks to Dr. Zhizhong Gong and Dr. Baoqi Fan for their suggestions of this study. Thanks to patient/participant advisors in the Health Management Centre for their assistance. Thanks to SC's friends Ms. Sarah Higbee-Tindell, Ms. Chu Yu, and Ms. Qingya Wu for writing assistance of grammar modification.

Competing interests: All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/coi_disclosure.pdf and declare: no support from any organization for the submitted work; no financial relationships with any organization that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.

Contributors: SC and YZ are joint first authors. SC contributed to study concept and design. SC wrote the first draft of the protocol manuscript. ZC supervised the process. YZ and JS revised the manuscript after feedback from all authors. YZ coordinates the conducting of this study. All authors reviewed the manuscript and approved the final version of the manuscript.

Data sharing statement: No additional data are available.

Patient consent: Consent will be obtained in the enrollment process.

Ethics approval: The Protocol is approved by the Ethics Committee of the first affiliated hospital to Army Medical University (KY201839).

References

1. E. W. Gregg, J. E. Shaw. Global Health Effects of Overweight and Obesity. *N Engl J Med* 2017;377(1):80-81. doi: 10.1056/NEJMe1706095 pmid:286042262017-07-06].
2. A. Afshin, M. H. Forouzanfar, M. B. Reitsma, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. *N Engl J Med* 2017;377(1):13-27. doi: 10.1056/NEJMoa1614362 pmid:286041692017-07-06].
3. Y. F. Wang, M. X. Sun, H. Xue, et al. [Understanding the China Blue Paper on Obesity Prevention and Control and policy implications and recommendations for obesity prevention and control in China]. *Zhonghua Yu Fang Yi Xue Za Zhi* 2019;53(9):875-84. doi: 10.3760/cma.j.issn.0253-9624.2019.09.003 pmid:314740672019-09-06].
4. L. Hu, X. Huang, C. You, et al. Prevalence of overweight, obesity, abdominal obesity and obesity-related risk factors in southern China. *PLOS ONE* 2017;12(9):e183934. doi: 10.1371/journal.pone.0183934 pmid:289103012017-01-20].
5. Y. Wang, J. Mi, X. Y. Shan, Q. J. Wang, K. Y. Ge. Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China. *Int J Obes (Lond)* 2007;31(1):177-88. doi: 10.1038/sj.ijo.0803354 pmid:166521282007-01-01].
6. Shuping Z. Changes in prevalence of overweight and obesity in a community in Chongqing from 2003 - 2013. *Chongqing Medicine* 2017;29(46):4108.
7. S. Stringhini, C. Carmeli, M. Jokela, et al. Socioeconomic status and the 25 x 25 risk factors as determinants of premature mortality: a multicohort study and meta-analysis of 1.7 million men and women. *LANCET* 2017;389(10075):1229-37. doi: 10.1016/S0140-6736(16)32380-7 pmid:28159391.[Copyright (c) 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. Published by Elsevier Ltd.. All rights reserved.:*2017-03-25].
8. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *LANCET* 2016;388(10053):1659-724. doi: 10.1016/S0140-6736(16)31679-8 pmid:27733284.[Copyright (c) 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. Published by Elsevier Ltd.. All rights reserved.:*2016-10-08].
9. B. Akinci, I. Yeldan, S. Celik, I. Satman. Physical Activity Indicators, Metabolic Biomarkers, and Comorbidity in Type 2 Diabetes. *Res Q Exerc Sport* 2019;90(4):690-98. doi: 10.1080/02701367.2019.1645269 pmid:314794022019-12-01].
10. World Health Organization. Physical Inactivity: A Global Public Health Problem. In, 2019.
11. I. M. Lee, E. J. Shiroma, F. Lobelo, et al. Effect of physical inactivity on major

1
2
3 506 non-communicable diseases worldwide: an analysis of burden of disease and life expectancy.
4 507 *LANCET* 2012;380(9838):219-29. doi: 10.1016/S0140-6736(12)61031-9
5 508 pmid:228189362012-07-21].
6
7 509 12. A. E. Bauman, R. S. Reis, J. F. Sallis, et al. Correlates of physical activity: why are some people
8 510 physically active and others not? *LANCET* 2012;380(9838):258-71. doi:
9 511 10.1016/S0140-6736(12)60735-1 pmid:228189382012-07-21].
10 512 13. J. F. Sallis, E. Cerin, T. L. Conway, et al. Physical activity in relation to urban environments in 14
11 513 cities worldwide: a cross-sectional study. *LANCET* 2016;387(10034):2207-17. doi:
12 514 10.1016/S0140-6736(15)01284-2 pmid:27045735.[Copyright (c) 2016 Elsevier Ltd. All rights
13 515 reserved.:*2016-05-28].
14 516 14. M. Karineniemi, T. Lankila, T. Ikaheimo, H. Koivumaa-Honkanen, R. Korpelainen. The Built
15 517 Environment as a Determinant of Physical Activity: A Systematic Review of Longitudinal
16 518 Studies and Natural Experiments. *ANN BEHAV MED* 2018;52(3):239-51. doi:
17 519 10.1093/abm/kax043 pmid:295386642018-02-17].
18 520 15. T. Althoff, R. Sosic, J. L. Hicks, et al. Large-scale physical activity data reveal worldwide activity
19 521 inequality. *NATURE* 2017;547(7663):336-39. doi: 10.1038/nature23018
20 522 pmid:286930342017-07-20].
21 523 16. A. K. Porter, D. A. Rodriguez, B. G. Frizzelle, K. R. Evenson. The Association between
22 524 Neighborhood Environments and Physical Activity from Pregnancy to Postpartum: a Prospective
23 525 Cohort Study. *J URBAN HEALTH* 2019;96(5):703-19. doi: 10.1007/s11524-019-00376-y
24 526 pmid:313424032019-10-01].
25 527 17. R. Murillo, L. M. Reesor, D. C. Hernandez, E. M. Obasi. Neighborhood Walkability and Aerobic
26 528 Physical Activity among Latinos. *AM J HEALTH BEHAV* 2019;43(4):802-11. doi:
27 529 10.5993/AJHB.43.4.13 pmid:312390222019-07-01].
28 530 18. R. Larouche, S. Blanchette, G. Faulkner, et al. Correlates of Children's Physical Activity: A
29 531 Canadian Multisite Study. *Med Sci Sports Exerc* 2019;51(12):2482-90. doi:
30 532 10.1249/MSS.0000000000002089 pmid:313063032019-12-01].
31 533 19. S. Amagasa, S. Inoue, N. Fukushima, et al. Associations of neighborhood walkability with
32 534 intensity- and bout-specific physical activity and sedentary behavior of older adults in Japan.
33 535 *GERIATR GERONTOL INT* 2019;19(9):861-67. doi: 10.1111/ggi.13730 pmid:31290251.[(c)
34 536 2019 Japan Geriatrics Society.:*2019-09-01].
35 537 20. X. Jia, Y. Yu, W. Xia, et al. Cardiovascular diseases in middle aged and older adults in China: the
36 538 joint effects and mediation of different types of physical exercise and neighborhood greenness and
37 539 walkability. *ENVIRON RES* 2018;167:175-83. doi: 10.1016/j.envres.2018.07.003
38 540 pmid:30029039.[Copyright (c) 2018 Elsevier Inc. All rights reserved.:*2018-11-01].
39 541 21. C. M. Nightingale, E. S. Limb, B. Ram, et al. The effect of moving to East Village, the former
40 542 London 2012 Olympic and Paralympic Games Athletes' Village, on physical activity and
41 543 adiposity (ENABLE London): a cohort study. *Lancet Public Health* 2019;4(8):e421-30. doi:
42 544 10.1016/S2468-2667(19)30133-1 pmid:31345752.[Copyright (c) 2019 The Author(s). Published
43 545 by Elsevier Ltd. This is an Open
44 546 Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All
45 547 rights reserved.:*2019-08-01].
46 548 22. A. M. Chudyk, H. A. McKay, M. Winters, J. Sims-Gould, M. C. Ashe. Neighborhood walkability,
47 549 physical activity, and walking for transportation: A cross-sectional study of older adults living on
48
49
50
51
52
53
54
55
56
57
58
59
60

- low income. *BMC GERIATR* 2017;17(1):82. doi: 10.1186/s12877-017-0469-5 pmid:283956722017-04-10].
23. Z. Sun, K. Y. Lai, S. Bell, I. Scott, X. Zhang. Exploring the Associations of Walking Behavior with Neighborhood Environments by Different Life Stages: A Cross-Sectional Study in a Smaller Chinese City. *Int J Environ Res Public Health* 2019;17(1) doi: 10.3390/ijerph17010237 pmid:319056932019-12-28].
 24. C. Sarkar, C. Webster, J. Gallacher. Neighbourhood walkability and incidence of hypertension: Findings from the study of 429,334 UK Biobank participants. *Int J Hyg Environ Health* 2018;221(3):458-68. doi: 10.1016/j.ijheh.2018.01.009 pmid:29398408.[Copyright (c) 2018 Elsevier GmbH. All rights reserved.:*2018-04-01].
 25. R. Zandieh, J. Flacke, J. Martinez, P. Jones, M. van Maarseveen. Do Inequalities in Neighborhood Walkability Drive Disparities in Older Adults' Outdoor Walking? *Int J Environ Res Public Health* 2017;14(7) doi: 10.3390/ijerph14070740 pmid:286862192017-07-07].
 26. Dana Jeffrey, Claire Boulangé, Billie Giles-Corti, Simon Washington, Lucy Gunn. Using walkability measures to identify train stations with the potential to become transit oriented developments located in walkable neighbourhoods. *J TRANSP GEOGR* 2019;76:221-31. doi: https://doi.org/10.1016/j.jtrangeo.2019.03.0092019-01-01].
 27. M. I. Creatore, R. H. Glazier, R. Moineddin, et al. Association of Neighborhood Walkability With Change in Overweight, Obesity, and Diabetes. *JAMA* 2016;315(20):2211-20. doi: 10.1001/jama.2016.5898 pmid:272186302016-05-24].
 28. P. James, M. A. Kioumourtzoglou, J. E. Hart, et al. Interrelationships Between Walkability, Air Pollution, Greenness, and Body Mass Index. *EPIDEMIOLOGY* 2017;28(6):780-88. doi: 10.1097/EDE.0000000000000724 pmid:287675142017-11-01].
 29. R. Yu, O. Cheung, K. Lau, J. Woo. Associations between Perceived Neighborhood Walkability and Walking Time, Wellbeing, and Loneliness in Community-Dwelling Older Chinese People in Hong Kong. *Int J Environ Res Public Health* 2017;14(10) doi: 10.3390/ijerph14101199 pmid:289912052017-10-09].
 30. D. R. Michanowicz, S. R. Williams, J. J. Buonocore, et al. Population allocation at the housing unit level: estimates around underground natural gas storage wells in PA, OH, NY, WV, MI, and CA. *Environ Health* 2019;18(1):58. doi: 10.1186/s12940-019-0497-z pmid:312807232019-07-08].
 31. H. Brath, S. J. Kim, R. D. Savage, et al. Neighborhood Walkability of Retirement Homes: A Cross-Sectional Cohort Study. *J AM MED DIR ASSOC* 2019;20(1):105-06. doi: 10.1016/j.jamda.2018.09.007 pmid:304016092019-01-01].
 32. Y. Zhao, P. K. Chung. Neighborhood environment walkability and health-related quality of life among older adults in Hong Kong. *Arch Gerontol Geriatr* 2017;73:182-86. doi: 10.1016/j.archger.2017.08.003 pmid:28822919.[Copyright (c) 2017 Elsevier B.V. All rights reserved.:*2017-11-01].
 33. B. I. Chen, M. C. Hsueh, R. Rutherford, J. H. Park, Y. Liao. The associations between neighborhood walkability attributes and objectively measured physical activity in older adults. *PLOS ONE* 2019;14(9):e222268. doi: 10.1371/journal.pone.0222268 pmid:314910152019-01-20].
 34. M. Rastovic, B. Srdic-Galic, O. Barak, E. Stokic, S. Polovina. AGING, HEART RATE VARIABILITY AND METABOLIC IMPACT OF OBESITY. *ACTA CLIN CROAT*

- 2019;58(3):430-38. doi: 10.20471/acc.2019.58.03.05 pmid:319697542019-09-01].
35. E. Cerin, T. L. Conway, A. Barnett, et al. Development and validation of the neighborhood environment walkability scale for youth across six continents. *Int J Behav Nutr Phys Act* 2019;16(1):122. doi: 10.1186/s12966-019-0890-6 pmid:317960752019-12-03].
36. N. A. Fini, J. Bernhardt, A. E. Holland. Low gait speed is associated with low physical activity and high sedentary time following stroke. *DISABIL REHABIL* 2019:1-08. doi: 10.1080/09638288.2019.1691273 pmid:317553112019-11-22].
37. M. Martinez-Ferran, F. de la Guia-Galipienso, F. Sanchis-Gomar, H. Pareja-Galeano. Metabolic Impacts of Confinement during the COVID-19 Pandemic Due to Modified Diet and Physical Activity Habits. *NUTRIENTS* 2020;12(6) doi: 10.3390/nu12061549 pmid:324665982020-05-26].
38. N. G. Nelson, M. J. Weingarten, W. X. Law, D. T. Sangiamo, N. C. Liang. Joint and separate exposure to alcohol and (9)-tetrahydrocannabinol produced distinct effects on glucose and insulin homeostasis in male rats. *Sci Rep* 2019;9(1):12025. doi: 10.1038/s41598-019-48466-w pmid:314276272019-08-19].
39. F. J. Raal, J. Tuomilehto, A. C. Sposito, et al. Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies. *J CLIN LIPIDOL* 2019;13(5):735-43. doi: 10.1016/j.jacl.2019.06.006 pmid:31377052.[Copyright (c) 2019 National Lipid Association. Published by Elsevier Inc. All rights reserved.:*2019-09-01].
40. Yi Zhao, Mizuki Tomita, Keitarou Hara, et al. Effects of topography on status and changes in land-cover patterns, Chongqing City, China. *LANDSC ECOL ENG* 2014;10(1):125-35. doi: 10.1007/s11355-011-0155-22014-01-01].
41. J. Lv, L. Qi, C. Yu, et al. Consumption of spicy foods and total and cause specific mortality: population based cohort study. *BMJ* 2015;351:h3942. doi: 10.1136/bmj.h3942 pmid:26242395.[(c) Lv et al 2015.:*2015-08-04].
42. WalkScore. Walk Score Methodology. In, 2020.
43. Ying Long. The Large-Scale Calculation of “WalkScore” of Main Cities in China. *New Architecture* 2018(3):4-08.
44. Tencent. Wechat official website. In, 2020.
45. Wei Tian, Jitian Song, Zhanyong Li, Pieter de Wilde. Bootstrap techniques for sensitivity analysis and model selection in building thermal performance analysis. *APPL ENERG* 2014;135:320-28. doi: <https://doi.org/10.1016/j.apenergy.2014.08.110>2014-01-01].
46. H. Kim, Y. Choi, J. Ma, et al. The Neighborhood Environment Walkability Scale for the Republic of Korea: Reliability and Relationship with Walking. *IRAN J PUBLIC HEALTH* 2016;45(11):1427-35. pmid:280320602016-11-01].
47. D. Adlakha, J. A. Hipp, R. C. Brownson. Adaptation and Evaluation of the Neighborhood Environment Walkability Scale in India (NEWS-India). *Int J Environ Res Public Health* 2016;13(4):401. doi: 10.3390/ijerph13040401 pmid:270493942016-04-02].
48. L. C. Messer, J. S. Jagai, K. M. Rappazzo, D. T. Lobdell. Construction of an environmental quality index for public health research. *Environ Health* 2014;13(1):39. doi: 10.1186/1476-069X-13-39 pmid:248864262014-05-22].



Participants who receive health examination in the Health Management Centre


Inclusion/exclusion criteria




Home and workplace addresses:
Walkscore

Wechat Mini App
in smartphone:
Daily steps

Health information
from health examination:
BMI etc.






<https://openstreetmap.org/copyright> <https://openstreetmap.org>

Copyright OpenStreetMap and contributors, under an open license. For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

<https://www.openstreetmap.org/#map=12/29.5442/106.6615&layers=C>



都江堰市 Dujiangyan
彭州市 Pengzhou
金堂县 Jintang
新都区 Xindu
成都市 Chengdu
元通镇 Yuantong
大划镇 Dahua
新津县 Xinjin
公义镇 Gongyi
视高街道 Shigao
眉山市 Meishan
仁寿县 Renshou
青神县 Qingshen
井研县 Jingyan
乐山市 Leshan
五通桥区 Wutongqiao
犍为县 Qianwei
中江县 Zhongjiang
幸福镇 Xingfu
双 Shua
三星镇
简阳市 Jianyang
三岔镇 Sancha
江源镇
资阳市 Ziyang
北斗镇 Beidou
仁寿县 Renshou
井研县 Jingyan
乐山市 Leshan
五通桥区 Wutongqiao
犍为县 Qianwei
射洪市 Shehong
天福镇 Tianfu
大英县 Daying
遂宁市 Suining
安居区 Anju
安岳县 Anyue
资中县 Zizhong
威远县 Weiyuan
自贡市 Zigong
富全镇 Fuquan
富顺县 Fushun
隆昌市 Longchang
泸县 Lu
西充县 Xichong
同德乡 Tongde
蓬溪县 Penxi
天福镇 Tianfu
遂宁市 Suining
安居区 Anju
安岳县 Anyue
资中县 Zizhong
威远县 Weiyuan
自贡市 Zigong
富全镇 Fuquan
富顺县 Fushun
隆昌市 Longchang
泸县 Lu
南充市 Nanchong
世阳镇 Shiyang
临江乡 Linjiang
金龙乡 Jinlong
三郎镇 Erlang
潼南区 Tongnan
维新镇 Weixin
合川区 Hechuan
北碚区 Beibei
璧山区 Bishan
永川区 Yongchuan
江津区 Jiangjin
安澜镇 Anlan
接龙镇 Jielong
南川区 Nanchuan
营山县 Yingshan
三汇镇 Sanhui
万寿镇 Wanshou
渠县 Qu
大有乡 Dayou
东岳乡 Dongyue
广安市 Guang'an
伏龙乡 Fulong
邻水县 Linshui
四海乡 Sihai
丰禾镇 Fenghe
万顺镇 Wanshun
包家镇 Baojia
三元镇 Sanyuan
拔山镇 Bashan
垫江县 Dianjiang
文星镇 Wenxing
回龙镇 Huilong
七星镇 Qixing
南岳镇 Nanyue
福善镇 Fushan
梁平区 Liangping
金鸡镇 Jinji
拔山镇 Bashan
丰都县 Fengdu
珍溪镇 Zhenxi
涪陵区 Fuling
五宝镇 Wubao
东温泉镇 Dongwenquan
安澜镇 Anlan
接龙镇 Jielong
南川区 Nanchuan
河图乡 Hetu
中桥乡 Zhongqiao
白马镇 Baima
武隆区 Wulong
Shuanghe
仙女湖镇 Xiannuhu
白涛街道
青羊镇 Qingyang

Supplementary Table 1. The timeline of study conduction

Approval of ethic committee	2018 July 10 th
Completion of clinical registration on Chinese Clinical Trial Registry Platform	2018 August 9 th
Date collection of demographic data and home/workplace addresses of participants	2019 October
Development of Wechat mini App for recording daily steps	2020 January
Previous data checking and data collection of questionnaire and health examination of participants	2020 March-May
Date collection of daily steps of participants by Wechat mini App	2020 June
Follow-up: Data collection of questionnaire, health examination of participants, and daily steps in one month	2020 December – 2021 February
Follow-up: Data collection of questionnaire, health examination of participants, and daily steps in one month	2021 December – 2022 February
Follow-up: Data collection of questionnaire, health examination of participants, and daily steps in one month	2022 December – 2023 February

Questionnaire

Part One: Basic Personal Information

1. Name: _____
2. Physical Examination Number: _____
3. Birthplace: City_____, Province_____
4. Present Address: Number_____, Neighborhood Committee/Village_____,
Township/Street_____, District/County_____, City_____
Province_____
5. Work Address: Number_____, Neighborhood Committee/Village_____,
Township/Street_____, District/County_____, City_____
Province_____
6. Except for home and office, is there any other place you are frequently present?
- ☐Yes ☐No If yes, how long will you spend in this place in one week? ____hours
7. ID Number: _____
8. Nationality: ☐The Han Nationality ☐National Minority: _____
9. Blood Type: _____
10. Height: _____ cm
11. Weight: _____ kg
12. Education Level:
- ☐Did not attend school normally ☐Primary school or below
- ☐Junior high school ☐High school and secondary technical school
- ☐Junior college ☐Undergraduate college
- ☐Master degree and above

13. Category of Employment:

- ☐ Company employee ☐ House ☐ Student
- ☐ Active duty soldier ☐ Freelancer ☐ Industrial worker
- ☐ Self-employed people ☐ Full-time driver
- ☐ Service and sales personnel ☐ Professional and technical personnel
- ☐ Civil servant, personnel of public institutions and state-owned enterprises
- ☐ Farmers, herdsmen and fishermen ☐ Others

14. Are you currently customer of Wechat daily step calculator?

- ☐ Yes ☐ No

15. In the past week, what is your average step recorded by Wechat daily step calculator, or other step recorder? _____steps

Part Two: Family History and Personal Health Status

1. Family History (Choose the diseases which your relatives are / were diagnosed with at present / in the past from those listed below)

Are / were your parents, brothers or sisters currently diagnosed with the following diseases?
(multiple choice, put a √ under the options)

Diseases	Father	Mother	Brother	Sister
Lung cancer				
Liver cancer				
Gastric cancer				
Esophageal cancer				
Colorectal cancer				
Thyroid cancer				
Prostate cancer				
Cervical cancer				
Endometrial cancer				
Ovarian cancer				
Breast cancer				
Diabetes mellitus				
Hypertension				
Obesity				
Gout (hyperuricemia)				
Hyperlipidemia				
Asthma				
Chronic obstructive pulmonary (chronic bronchitis, emphysema)				
Stroke				
Coronary heart disease or myocardial infarction				
Osteoporosis				
Mental disease				
Other diseases				
None				

2. Personal History of Diseases

Whether the following diseases are / were diagnosed? (multiple choice)

- ☐ Lung cancer ☐ Liver cancer ☐ Gastric cancer ☐ Esophageal cancer
☐ Colorectal cancer ☐ Thyroid cancer ☐ Prostate cancer ☐ Cervical cancer
☐ Endometrial cancer ☐ Ovarian cancer ☐ Breast cancer ☐ Diabetes
☐ Hypertension ☐ Hyperlipidemia ☐ Stroke ☐ Asthma
☐ Osteoporosis ☐ Fracture ☐ Mental disorders ☐ Neurasthenia
☐ Gout (hyperuricemia) ☐ Thyroid disease (thyroiditis, nodule)
☐ Chronic cholecystitis and cholelithiasis ☐ Gastritis or duodenal ulcer
☐ Coronary heart disease or myocardial infarction
☐ Prostatic disease (hyperplasia of prostate, hypertrophy)
☐ Chronic obstructive pulmonary disease (chronic bronchitis, emphysema)
☐ Chronic liver disease (☐ hepatitis B, ☐ hepatitis C, ☐ fatty liver, ☐ alcoholic liver, ☐ liver cirrhosis)
☐ Chronic glomerulonephritis (nephritis, nephrotic syndrome, chronic renal insufficiency)
☐ Chronic breast diseases (hyperplasia of mammary glands, nodules, adenosis, cysts, etc.)
☐ Chronic gynecologic diseases (uterine fibroids, ovarian cysts, inflammations, etc.)
☐ History of operation: (The operation name:____)
☐ Other diseases ☐ None of the above diseases

3. Medication History

Do you take the following medicines for a long term? (continuous use for above 6 months, and more than once per day on average)

- ☐ Hypotensive drugs ☐ Beta blockers
☐ Psychotropic drugs ☐ Antiarrhythmic drugs

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- | | |
|---|--|
| <input type="checkbox"/> Uric acid-lowering drugs | <input type="checkbox"/> Hypoglycemic drugs |
| <input type="checkbox"/> Sedative or hypnotic drugs | <input type="checkbox"/> Hormone drugs |
| <input type="checkbox"/> Chinese herbal medicines | <input type="checkbox"/> Antipyretic analgesics |
| <input type="checkbox"/> Antiplatelet drugs such as aspirin | <input type="checkbox"/> Lipid-modulating drugs (lipid-lowering drugs) |
| <input type="checkbox"/> Angiotensin-converting enzyme inhibitors | <input type="checkbox"/> Anti-asthmatic drugs |
| <input type="checkbox"/> Others | <input type="checkbox"/> None |

For peer review only

Part Three: Eating Habits and Lifestyle

1. Eating Habit

1.1. Generally speaking, how many days during a week will you eat the following food on average? (single choice)

Rice	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Noodles	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Coarse Cereals	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Meat (pigs, cattle, sheep, poultry)	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Fish or other aquatic products	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Fresh vegetable and fruit	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Milk and dairy products	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Eggs and their products	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Beans and bean products	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Dessert (pastries, candy, etc)	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Fried food	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat
Pickled, smoked food	<input type="checkbox"/> 5 - 7 days	<input type="checkbox"/> 3 - 4 days	<input type="checkbox"/> 1 - 2 days	<input type="checkbox"/> <1day or never eat

1.2. In the past year, did you take the following nutrients for at least one month?

(except for ginseng)

☐ Cod liver oil / fish oil

☐ Ginseng (at least five times a year)

☐ Vitamin

☐ Other health supplements

☐ Calcium / iron / zinc

1.3. Have you ever experienced severe food shortages in your life?

☐ Yes ☐ No If not, please turn to question 4

1.3.1. In which year did you experience the most severe food shortage? _____

1.3.2. When you were experiencing the most severe food shortage:

1.3.2.1. Did your weight decrease significantly?

☐Yes ☐ No If yes, it dropped by ____ kilograms

1.3.2.2. Did you suffer from edema, severe anemia and other diseases caused by food shortages such as? ☐Yes ☐ No

1.4. In the past month, how often did you eat spicy food?

☐Never / almost never ☐1-2 days a week
☐A few times, but less than once a week on average
☐3-5 days a week ☐Every day or almost every day

1.5. How old did you begin to eat spicy food every week? ____ years old

1.6. Do you like slightly spicy food or very spicy food?

☐Slightly spicy ☐Spicy ☐Very spicy

1.7. Do you order food online?

☐Yes ☐No

1.8. How often will you order food online in one week? ____Times

1.9. What are the categories of online-ordered food you select?

☐Noodles with soup ☐Rice ☐Fried noodles ☐Dumplings
☐Sweet food, eg.cake ☐Drinks ☐Others

1.10. How often will you eat outside home (not including online order food)?
____Times

2. Smoking

Do you smoke? <input type="checkbox"/> Yes. Please answer questions 2.1, 2.2,2.5 and 2.6 <input type="checkbox"/> No. Please answer questions 2.7-2.8. <input type="checkbox"/> Quit smoking. (have quit smoking for more than one month) Please answer questions 2.3-2.6.	2.1. You began to smoke at the age of ____.
	2.2. You smoke ____ cigarettes per day on average.
	2.3. You quitted smoking at the age of ____.
	2.4. Before quitting smoking, you smoked ____ cigarettes per day on average.
	2.5. Which type of cigarettes do you smoke at present/or did you smoke before quitting? <input type="checkbox"/> Filter cigarette <input type="checkbox"/> Non-filter Cigarettes <input type="checkbox"/> Cigar <input type="checkbox"/> Hand-rolled cigarette / tobacco <input type="checkbox"/> Tobacco pipe / waterpipe smoking
	2.6. Which organ do you suck the smoke into?

4.3. Did you need to take medicine to help you fall asleep in the past month?
(medicine prescribed by the doctor or purchased by yourself)

- ☐No ☐ < Once every week on average
☐ Once-twice every week on average ☐ ≥ 3 times every week on average

5. Physical activity

5.1. In the past year, what is your activity status during work?

- ☐ Sedentary ☐ Standing ☐ Activity with medium amount
☐ Activity with heavy work load ☐ Retired or disabled to work

5.2. What is your average working hour in one week? _____ hours

5.3. In the past your, what is your transportation way to go to work?

- ☐ Walking ☐ Driving ☐ Taking a bus
☐ Riding a bike ☐ Work at home ☐ Others
or the place closed to home

5.4. How long is the commuting time of your work? _____ min

5.5. In the past one year, what is your physical activity frequency?

- ☐ Never ☐ 1-3 times one month ☐ 1-2 times one week
☐ 3 -5 times one week ☐ Almost everyday

5.6. What is the exercise way you did the most frequently?

- ☐ Taichi/Walking ☐ Fast walking ☐ Running/or other aerobics
☐ Swimming ☐ Ball game ☐ Others(such as hiking)

5.7. During the last 7 days, on how many days did you do vigorous physical activities
like heavy lifting, digging, heavy construction, or climbing up stairs as part of your
work?

_____ days per week

5.8. How much time did you usually spend on one of those days doing vigorous
physical activities as part of your work?

_____ hours per day, _____ minutes per day

5.9. During the last 7 days, on how many days did you do moderate physical activities like carrying light loads as part of your work? Please do not include walking.

_____ days per week

5.10. How much time did you usually spend on one of those days doing moderate physical activities as part of your work?

_____ hours per day, _____ minutes per day

5.11. During the last 7 days, on how many days did you walk for at least 10 minutes at a time as part of your work?

_____ days per week

5.12. How much time did you usually spend on one of those days walking as part of your work?

_____ hours per day, _____ minutes per day

5.13. During the last 7 days, how much time did you usually spend sitting on a weekday?

_____ hours per day, _____ minutes per day

5.14. Did you use sport watch or app for record steps or heart rate?

☐ Yes ☐ No

If yes, the name of sport watch is _____, the name of the sport app is _____

6. Others

6.1. Are you satisfied with your current living conditions?

☐ Cannot be more satisfied ☐ Basically satisfied

☐ Ordinary ☐ Dissatisfied ☐ Very dissatisfied

6.2. Did you experience the events that have a significant impact on your life in the past two years, such as those listed below?

☐ Marital separation/divorce ☐ Serious trauma or car accident

☐ Unemployment / laid-off / retirement ☐ Death of spouse

☐ Serious family diversity and conflicts ☐ Violent attacks / rapes

☐ Loss of economic resources / liabilities

☐ Bankruptcy of self-owned business or family economic breakdown

☐ Death or serious diseases of other family members

☐ Serious natural disasters (such as drought, waterlogging, etc.)

☐ None

6.3. In the past year, are you under great mental stress in work and life?

- ☐No pressure ☐Little pressure ☐Ordinary
☐Great pressure ☐Extremely great pressure

6.4. In the past one year, is any change in your body weight?

- ☐No ☐Add at least 2.5kg ☐Lose at least 2.5kg

6.5. In the past one year, do you using drugs or controlling diet intake in order to lose weight?

- ☐Yes ☐No

6.6. Could you remember your body weight when you was at age of 25?

_____kg; ☐Not applicable

Signature_____

Variable category	Name of variable	Normal limits or categories	Definition of variables	Data resources
Primary outcomes	body mass index	18.5-24kg/m2	outcome	calculate from health examination information
	daily steps in one month		mediator and outcome	Wechat mini application
Secondary outcomes	fasting blood glucose (GLU)	3.6-6.1 (mmol/L)	outcome	health examination
	total cholesterol (TC)	3.1-5.7 (mmol/L)	outcome	health examination
	triglyceride (Tg)	0.4-1.73 (mmol/L)	outcome	health examination
	low density lipoprotein cholesterin (LDL-C)	2.07-3.1 (mmol/L)	outcome	health examination
	high density lipoprotein cholesterin (HDL-C)	0.9-2 (mmol/L)	outcome	health examination
	body composition	mass percentage of fat	outcome	health examination
Exposure variables	WalkScore corresponding to home address	0-100	exposure	calculate from questionnaire information
	WalkScore corresponding to workplace address	0-100	exposure	calculate from questionnaire information
Other variables	height			health examination
	weight			health examination
	age	16 - 65 years old	possible confounding	questionnaire
	gender	male; female	possible confounding	questionnaire
	job		possible confounding	questionnaire
	education	under primary school; primary school, middle school; bachelor; master and a	possible confounding	questionnaire
	smoking status	giving up; never; sometimes smoke; frequently smoke	other factors will influence outcome	questionnaire
	alcohol consumption	giving up; never; sometimes drink; frequently drink	other factors will influence outcome	questionnaire
	online food order habit	never; sometimes order; frequently order	possible confounding	questionnaire
	eating diet	more details showed in questionnnaire	other factors will influence outcome	questionnaire
	physical activity	more details showed in questionnnaire	possible confounding	questionnaire

The name of health examination	Specific name of items	Normal limits or result categories
Five items of thyroid function	Free triiodothyronine (FT3)	2.0-6.6 pmol/L
	Free thyroxine (FT4)	10.3-31.0 pmol/L(0.8~2.3ng/dL)
	Thyroid-stimulating hormone (TSH)	0.3-4.5 uIU/mL
	Total triiodothyronine (TT3)	1.8-2.9 nmol/L(115~190ng/dL)
	Total thyroxine (TT4)	65-155 nmol/L(5.0~12.0µg/dL)
12-leads electrocardiogram		N=Normal; A=abnormal
Ultrasound (splenorenal major abdominal and portal vein)		
	Liver	N=Normal; A=abnormal
	Gallbladder	N=Normal; A=abnormal
	Pancreas	N=Normal; A=abnormal
	Spleen	N=Normal; A=abnormal
	Bilateral kidneys	N=Normal; A=abnormal
	Portal vein	N=Normal; A=abnormal
Carcinoembryonic antigen (CEA)		0-5 (ng/ml)
Liver function	Albumin (Alb)	38-51 (g/L)
	Albumin/Globulin	1.2-2.5
	Gamma-glutamyl transpeptidase (GGT)	4-50 (IU/L)
	Alanine amino transferase (ALT)	0-42 (IU/L)
	Aspartate amino transferase (AST)	0-42 (IU/L)
	Alkaline Phosphatase (ALP)	34-114 (IU/L)
	Globulin (G)	25-38 (g/L)
	Total protein (TP)	66-83 (g/L)
Alpha-fetoprotein (AFP)		0-20 (ng/ml)
Urine routine	Potential of hydrogen (PH)	4.6-8.0
	Urine leukocyte (LEU)	Negative or positive
	Specific gravity (SG)	1.003-1.03
	Bilirubin (BIL)	Negative or positive
	Urobilinogen (URO)	N=Normal; A=abnormal
	Urine protein (PRO)	Negative or positive
	Urine Casts	Negative or positive
	Urine erythrocyte (ERY)	Negative or positive
	Urine pus cells	Negative or positive
	Urine colour	Negative or positive
	Uroepithelial cell (U-Epc)	Negative or positive
	Urine sugar (U-GLU)	Negative or positive
	Urine ketone (KET)	Negative or positive
	Urine nitrite (NIT)	Negative or positive
	Urine transparency	Negative or positive

	Urinary mucous silk (U-MUCS)	Negative or positive
	Creatinine (CR)	45-84 (μmol/L)
	Blood urea nitrogen (UN)	1.7-8.3 (mmol/L)
	Uric acid (UN)	155-428 (μmol/L)
	Fasting blood glucose (GLU)	3.6-6.1 (mmol/L)
	Serum cystatin c (Cys-c)	0.5-1.1 (mg/L)
Blood routine		
	white blood cell (WBC)	3.5-9.5 (10 ⁹ /L)
	Percent monocytes (MON%)	3-10 (%)
	Monocytes (MON)	0.1-0.6 (10 ⁹ /L)
	Red blood cell (RBC)	3.8-5.1 (10 ¹² /L)
	Red blood cell distribution width (SD)	11-16 (%)
	Red blood cell distribution width (CV)	37-54 (fL)
	Hematokrit (HCT)	35-45 (%)
	Percent lymphocyte (LYMPH%)	20-50 (%)
	Lymphocyte count (LYMPH)	1.1-3.2 (10 ⁹ /L)
	Mean corpuscular volume (MCV)	82-100 (fL)
	The average RBC hemoglobin content (MCH)	27-34 (pg)
	The average RBC hemoglobin concentration (MCH)	316-354 (g/L)
	mean platelet volume (MPV)	9-13 (fL)
	Basophilic cell percentage (BAS%)	0-1 (%)
	absolute basophil count (BAS)	0-0.06 (10 ⁹ /L)
	Acidophilic cell percentage (EOS%)	0.4-8 (%)
	Acidophil number (EOS)	0.02-0.52 (10 ⁹ /L)
	Hemoglobin (HGB)	115-150
	Platelet distribution width (PDW)	9-17 (%)
	blood platelet count (PLT)	125-350 (10 ⁹ /L)
	Thrombocytocrit (PCT)	N (%)
	Neutrophilic granulocyte percentage (NEU%)	40-75 (%)
	Neutrophilic granulocyte count (NEU)	1.8-6.3 (10 ⁹ /L)
Blood lipid		
	Total cholesterol (TC)	3.1-5.7 (mmol/L)
	Triglyceride (Tg)	0.4-1.73 (mmol/L)
	Low density lipoprotein cholesterin (LDL-C)	2.07-3.1 (mmol/L)
	High density lipoprotein cholesterin (HDL-C)	0.9-2 (mmol/L)
Two pairs of semi - hepatitis B		
	Hepatitis B e antibody (HBe)	Negative or positive
	Hepatitis B e antigen (HBeAg)	Negative or positive

	Hepatitis B surface antibody (HBs)	Negative or positive
	Hepatitis B surface antigen (HBsAg)	Negative or positive
	Hepatitis B core antibody (HBc)	Negative or positive
Ultrasound(bilateral mammary gland)		N=Normal; A=abnormal
Ultrasound(uterus, annex)		N=Normal; A=abnormal
Vaginal secretion examination	Trichomonad	Negative or positive
	Mycete	Negative or positive
	Cleanliness of leucorrhea	Negative or positive
Thinprep cytology test(TCT)		N=Normal; A=abnormal
Body composition		Mass percentage of fat, protein, and water

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract P2 (b) Provide in the abstract an informative and balanced summary of what was done and what was found P2
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported P3
Objectives	3	State specific objectives, including any prespecified hypotheses P3
Methods		
Study design	4	Present key elements of study design early in the paper P5-P6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection P4-P7
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up P4-P5 <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed P6 <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable P4-P7
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group P6-P7
Bias	9	Describe any efforts to address potential sources of bias P6-P7
Study size	10	Explain how the study size was arrived at P6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why P7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding P7 (b) Describe any methods used to examine subgroups and interactions P7 (c) Explain how missing data were addressed P7 (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed P7 <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses P6

Continued on next page

Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount) P7
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18	Summarise key results with reference to study objectives
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias P7
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence P7
Generalisability	21	Discuss the generalisability (external validity) of the study results P7
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.